NZ611805B2 - Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles - Google Patents
Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles Download PDFInfo
- Publication number
- NZ611805B2 NZ611805B2 NZ611805A NZ61180512A NZ611805B2 NZ 611805 B2 NZ611805 B2 NZ 611805B2 NZ 611805 A NZ611805 A NZ 611805A NZ 61180512 A NZ61180512 A NZ 61180512A NZ 611805 B2 NZ611805 B2 NZ 611805B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- lower alkoxy
- bubr1
- lower alkyl
- hydroxy
- Prior art date
Links
- 230000004044 response Effects 0.000 title claims abstract description 57
- 239000000090 biomarker Substances 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 title description 9
- 229940079593 drugs Drugs 0.000 title description 6
- 101700023103 BUB1B Proteins 0.000 claims abstract description 190
- 102100005257 BUB1B Human genes 0.000 claims abstract description 188
- 101700052048 BUBR1 Proteins 0.000 claims abstract description 181
- 150000001875 compounds Chemical class 0.000 claims abstract description 159
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 122
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 94
- 239000011780 sodium chloride Substances 0.000 claims abstract description 81
- 150000003839 salts Chemical class 0.000 claims abstract description 77
- -1 monoalkylamino Chemical group 0.000 claims abstract description 76
- 239000000651 prodrug Substances 0.000 claims abstract description 64
- 229940002612 prodrugs Drugs 0.000 claims abstract description 64
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 48
- 239000001257 hydrogen Substances 0.000 claims abstract description 48
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 47
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 44
- 125000001424 substituent group Chemical group 0.000 claims abstract description 43
- 201000010099 disease Diseases 0.000 claims abstract description 37
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 33
- 150000002367 halogens Chemical class 0.000 claims abstract description 32
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract description 31
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 31
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 29
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000012453 solvate Substances 0.000 claims abstract description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 23
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 16
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 14
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims abstract description 14
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims abstract description 14
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims abstract description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 14
- 125000004663 dialkyl amino group Chemical group 0.000 claims abstract description 14
- 125000004432 carbon atoms Chemical group C* 0.000 claims abstract description 11
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 7
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 6
- 210000004027 cells Anatomy 0.000 claims description 205
- 201000011510 cancer Diseases 0.000 claims description 53
- 108090001123 antibodies Proteins 0.000 claims description 38
- 102000004965 antibodies Human genes 0.000 claims description 38
- 210000001519 tissues Anatomy 0.000 claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims description 25
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 19
- 201000005202 lung cancer Diseases 0.000 claims description 17
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 15
- 206010017758 Gastric cancer Diseases 0.000 claims description 15
- 201000010881 cervical cancer Diseases 0.000 claims description 15
- 201000011549 stomach cancer Diseases 0.000 claims description 15
- 206010033128 Ovarian cancer Diseases 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 150000001408 amides Chemical class 0.000 claims description 12
- 206010003816 Autoimmune disease Diseases 0.000 claims description 11
- 230000000977 initiatory Effects 0.000 claims description 11
- 230000001613 neoplastic Effects 0.000 claims description 11
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 210000001124 Body Fluids Anatomy 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- 201000011231 colorectal cancer Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 206010025650 Malignant melanoma Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 201000005216 brain cancer Diseases 0.000 claims description 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 230000000955 neuroendocrine Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 70
- 102000028664 Microtubules Human genes 0.000 description 54
- 108091022031 Microtubules Proteins 0.000 description 54
- 210000004688 Microtubules Anatomy 0.000 description 54
- 108020004459 Small Interfering RNA Proteins 0.000 description 53
- 230000000694 effects Effects 0.000 description 42
- 239000002924 silencing RNA Substances 0.000 description 41
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 36
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 34
- 229950006344 Nocodazole Drugs 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 34
- 238000004166 bioassay Methods 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 29
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 27
- 229960001592 Paclitaxel Drugs 0.000 description 27
- 229960003048 Vinblastine Drugs 0.000 description 27
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 27
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 27
- 229930003347 taxol Natural products 0.000 description 27
- 239000000203 mixture Substances 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 22
- 150000007523 nucleic acids Chemical group 0.000 description 20
- 229960001338 colchicine Drugs 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000006722 reduction reaction Methods 0.000 description 15
- 206010059512 Apoptosis Diseases 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 14
- 230000004663 cell proliferation Effects 0.000 description 13
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 12
- 239000002609 media Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 230000030833 cell death Effects 0.000 description 11
- 230000000394 mitotic Effects 0.000 description 11
- 238000003364 immunohistochemistry Methods 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000003119 immunoblot Methods 0.000 description 8
- 238000002318 immunoblotting Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 230000001965 increased Effects 0.000 description 7
- 210000000056 organs Anatomy 0.000 description 7
- 230000001225 therapeutic Effects 0.000 description 7
- 102000000132 Alpha tubulin Human genes 0.000 description 6
- 108050008484 Alpha tubulin Proteins 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 6
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000012188 paraffin wax Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 101710027066 ALB Proteins 0.000 description 5
- 210000004072 Lung Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010047115 Vasculitis Diseases 0.000 description 5
- 238000001516 cell proliferation assay Methods 0.000 description 5
- 238000003795 desorption Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102100014001 ABCB1 Human genes 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 229940024606 Amino Acids Drugs 0.000 description 4
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 4
- 102000000131 Beta tubulin Human genes 0.000 description 4
- 108050008483 Beta tubulin Proteins 0.000 description 4
- PRDFBSVERLRRMY-UHFFFAOYSA-N Bisbenzimide Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 229950004398 Broxuridine Drugs 0.000 description 4
- 229920002676 Complementary DNA Polymers 0.000 description 4
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 4
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 4
- 108020004999 Messenger RNA Proteins 0.000 description 4
- 210000004080 Milk Anatomy 0.000 description 4
- 108091005503 Nucleic proteins Proteins 0.000 description 4
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000001028 anti-proliferant Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000003247 decreasing Effects 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000011068 load Methods 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 229920002106 messenger RNA Polymers 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000003196 serial analysis of gene expression Methods 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108060006672 BUB1 Proteins 0.000 description 3
- 102100005258 BUB1 Human genes 0.000 description 3
- 210000001185 Bone Marrow Anatomy 0.000 description 3
- 210000000988 Bone and Bones Anatomy 0.000 description 3
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M CHEMBL593252 Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 3
- 210000001072 Colon Anatomy 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 229940022766 EGTA Drugs 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- 206010027476 Metastasis Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 229920001850 Nucleic acid sequence Polymers 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 239000007759 RPMI Media 1640 Substances 0.000 description 3
- 210000000664 Rectum Anatomy 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 239000006143 cell culture media Substances 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000002596 correlated Effects 0.000 description 3
- 238000003235 crystal violet staining Methods 0.000 description 3
- 230000001472 cytotoxic Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001809 detectable Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000002496 gastric Effects 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- VUGRPJUREUOUIO-UHFFFAOYSA-N 2H-benzotriazol-4-yloxy-tris(dimethylamino)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)[P+](N(C)C)(N(C)C)OC1=CC=CC2=C1N=NN2 VUGRPJUREUOUIO-UHFFFAOYSA-N 0.000 description 2
- HJFCVJKLGPYQDB-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine Chemical compound C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 HJFCVJKLGPYQDB-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N Adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 210000003679 Cervix Uteri Anatomy 0.000 description 2
- 208000004921 Cutaneous Lupus Erythematosus Diseases 0.000 description 2
- 101710028159 DNTT Proteins 0.000 description 2
- 102100002445 DNTT Human genes 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229940034984 ENDOCRINE THERAPY ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Drugs 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108090001095 Immunoglobulin G Proteins 0.000 description 2
- 102000004851 Immunoglobulin G Human genes 0.000 description 2
- 102100011339 KLK3 Human genes 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 210000001365 Lymphatic Vessels Anatomy 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010061232 Lymphoproliferative disease Diseases 0.000 description 2
- 208000003250 Mixed Connective Tissue Disease Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010025310 Other lymphomas Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N Pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N Suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001541 Thymus Gland Anatomy 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 230000001640 apoptogenic Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- LSFOZQQVTWFMNS-UHFFFAOYSA-N avanbulin Chemical compound C1=CC(N)=CC=C1C(=O)CN1C2=CC=CC=C2N=C1C1=NON=C1NCCC#N LSFOZQQVTWFMNS-UHFFFAOYSA-N 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000035572 chemosensitivity Effects 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000009261 endocrine therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002055 immunohistochemical Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002452 interceptive Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 150000002829 nitrogen Chemical group 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001711 protein immunostaining Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 200000000008 restenosis Diseases 0.000 description 2
- 108091007521 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 238000010518 undesired secondary reaction Methods 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N (2S)-2-acetamido-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (E)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
- YBKSULBKIFNMCF-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[2-[4-(3-hydroxypropylamino)-1,2,5-oxadiazol-3-yl]benzimidazol-1-yl]ethanone;3-[[4-[1-[2-(4-chlorophenyl)-2-oxoethyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-yl]amino]propanenitrile Chemical compound OCCCNC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)C1=CC=C(Cl)C=C1.C1=CC(Cl)=CC=C1C(=O)CN1C2=CC=CC=C2N=C1C1=NON=C1NCCC#N YBKSULBKIFNMCF-UHFFFAOYSA-N 0.000 description 1
- 229920002483 18S ribosomal RNA Polymers 0.000 description 1
- FIONSPWWEQBPKZ-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-1-phenylethanone Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)C1=CC=CC=C1 FIONSPWWEQBPKZ-UHFFFAOYSA-N 0.000 description 1
- LBCZOTMMGHGTPH-UHFFFAOYSA-N 2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCO)C=C1 LBCZOTMMGHGTPH-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-J 2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O KCXVZYZYPLLWCC-UHFFFAOYSA-J 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- ULUDPLQFSRBULT-UHFFFAOYSA-N 3-[[4-[1-[(3,4-dimethylphenoxy)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-yl]amino]propanenitrile Chemical compound C1=C(C)C(C)=CC=C1OCN1C2=CC=CC=C2N=C1C1=NON=C1NCCC#N ULUDPLQFSRBULT-UHFFFAOYSA-N 0.000 description 1
- JDQDSEVNMTYMOC-UHFFFAOYSA-N 3-methylbenzenesulfonic acid Chemical compound CC1=CC=CC(S(O)(=O)=O)=C1 JDQDSEVNMTYMOC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-Aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- HBFNOXGYDVYEAJ-UHFFFAOYSA-N 4-[1-(phenoxymethyl)benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1COC1=CC=CC=C1 HBFNOXGYDVYEAJ-UHFFFAOYSA-N 0.000 description 1
- FRGOWFWLSTYAKH-UHFFFAOYSA-N 4-[1-[(4-fluorophenoxy)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1COC1=CC=C(F)C=C1 FRGOWFWLSTYAKH-UHFFFAOYSA-N 0.000 description 1
- 229940046932 4-aminosalicylic acid Drugs 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9H-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 201000004304 Addison's disease Diseases 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 208000005488 Adnexal and Skin Appendage Neoplasms Diseases 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 206010048594 Allergic granulomatous angiitis Diseases 0.000 description 1
- 208000004631 Alopecia Areata Diseases 0.000 description 1
- 208000008524 Alveolar Soft Part Sarcoma Diseases 0.000 description 1
- 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-N Armstrong's acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Azelaic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 102100013894 BCL2 Human genes 0.000 description 1
- 108060000885 BCL2 Proteins 0.000 description 1
- 102000036638 BRCA1 Human genes 0.000 description 1
- 108010042977 BRCA1 Protein Proteins 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 208000009137 Behcet Syndrome Diseases 0.000 description 1
- 201000008335 Behcet's disease Diseases 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N Benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N Bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N Citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N Cyclamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 210000004292 Cytoskeleton Anatomy 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 206010061811 Demyelinating polyneuropathy Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 101700057458 Drice Proteins 0.000 description 1
- 206010073508 Drug reaction with eosinophilia and systemic symptom Diseases 0.000 description 1
- 208000006922 Drug-Related Side Effects and Adverse Reaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- QXRSDHAAWVKZLJ-TYFQHMATSA-N Epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@@]2(C)CCC[C@@H]([C@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-TYFQHMATSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 210000001508 Eye Anatomy 0.000 description 1
- 208000007842 Fibroepithelial Neoplasms Diseases 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 208000007465 Giant Cell Arteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018381 Glomus tumour Diseases 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 description 1
- 206010060980 Granular cell tumour Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020718 Hyperplasia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000010159 IGA Glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 108090001122 Immunoglobulin A Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 201000007313 Kawasaki disease Diseases 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-O L-lysinium(1+) Chemical compound [NH3+]CCCC[C@H]([NH3+])C([O-])=O KDXKERNSBIXSRK-YFKPBYRVSA-O 0.000 description 1
- 102100000087 LARP6 Human genes 0.000 description 1
- 101700066207 LARP6 Proteins 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 208000007820 Lichen Sclerosus et Atrophicus Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 206010024515 Linear IgA disease Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 210000004324 Lymphatic System Anatomy 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- 206010027191 Meningioma Diseases 0.000 description 1
- 208000010153 Mesonephroma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 208000000811 Mesothelial Neoplasms Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 230000036091 Metabolic activity Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N Methyl bisulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 description 1
- 102000011279 Multidrug resistance protein 1 Human genes 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 206010028576 Myeloproliferative disease Diseases 0.000 description 1
- WIKSGWRDYPATMU-UHFFFAOYSA-N N-[2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-1-(4-bromophenyl)ethylidene]hydroxylamine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=NO)C1=CC=C(Br)C=C1 WIKSGWRDYPATMU-UHFFFAOYSA-N 0.000 description 1
- UZMYPBYAISNZHQ-UHFFFAOYSA-N N-[4-[1-[2-(4-chlorophenyl)-2-oxoethyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-yl]acetamide Chemical compound CC(=O)NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)C1=CC=C(Cl)C=C1 UZMYPBYAISNZHQ-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M N-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 210000000282 Nails Anatomy 0.000 description 1
- 210000003739 Neck Anatomy 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 208000004235 Neutropenia Diseases 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 210000003300 Oropharynx Anatomy 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 208000007312 Paraganglioma Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 210000000578 Peripheral Nerves Anatomy 0.000 description 1
- 206010034695 Pernicious anaemia Diseases 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N Phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035228 Plasma cell neoplasms Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 206010038294 Reiter's syndrome Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 description 1
- 101700074516 SSK1 Proteins 0.000 description 1
- 208000005511 Schoenlein-Henoch Purpura Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 208000002669 Sex Cord-Gonadal Stromal Tumors Diseases 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N Sodium molybdate Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N Sodium orthovanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 208000004841 Squamous Cell Neoplasms Diseases 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 206010043207 Temporal arteritis Diseases 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 206010044412 Transitional cell carcinoma Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000006786 Trophoblastic Neoplasm Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- BIABKPAXSLKGLN-UHFFFAOYSA-N [dimethylamino(2H-triazolo[4,5-b]pyridin-7-yloxy)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=NC2=C1N=NN2 BIABKPAXSLKGLN-UHFFFAOYSA-N 0.000 description 1
- CZQGINAUZYECAI-UHFFFAOYSA-N [dimethylamino-(2-oxopyridin-1-yl)oxymethylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CN(C)C(=[N+](C)C)ON1C=CC=CC1=O CZQGINAUZYECAI-UHFFFAOYSA-N 0.000 description 1
- NLWSBEIYMWSFEG-UHFFFAOYSA-O [dimethylamino-[(2-oxo-1H-pyridin-3-yl)oxy]methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=CNC1=O NLWSBEIYMWSFEG-UHFFFAOYSA-O 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 230000009789 autophagic cell death Effects 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- YCRYJWJNPWZJSR-UHFFFAOYSA-O butylideneazanium Chemical group [CH2-]CCC=[NH2+] YCRYJWJNPWZJSR-UHFFFAOYSA-O 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002113 chemopreventative Effects 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 230000001010 compromised Effects 0.000 description 1
- 230000003750 conditioning Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 201000003066 diffuse scleroderma Diseases 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 238000001861 endoscopic biopsy Methods 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 229930013349 epothilone B Natural products 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol EtOH Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- FFLYUXVZEPLMCL-UHFFFAOYSA-N ethylchloranuidyl formate Chemical compound CC[Cl-]OC=O FFLYUXVZEPLMCL-UHFFFAOYSA-N 0.000 description 1
- SIVVHUQWDOGLJN-UHFFFAOYSA-N ethylsulfamic acid Chemical group CCNS(O)(=O)=O SIVVHUQWDOGLJN-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 230000031376 exit from mitosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 201000005618 glomus tumor Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 201000005708 granuloma annulare Diseases 0.000 description 1
- 201000011580 granulomatous orchitis Diseases 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-O hydron;2H-tetrazole Chemical class C1=NN=[NH+]N1 KJUGUADJHNHALS-UHFFFAOYSA-O 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000003279 hypersensitivity reaction type IV disease Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 201000003088 limited scleroderma Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004880 lymph fluids Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229920001239 microRNA Polymers 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000017205 mitotic cell cycle checkpoint Effects 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000009368 muscle benign neoplasm Diseases 0.000 description 1
- 210000000663 muscle cells Anatomy 0.000 description 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 201000010791 peripheral nerve sheath neoplasm Diseases 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- HLIBNTOXKQCYMV-UHFFFAOYSA-N propylsulfamic acid Chemical compound CCCNS(O)(=O)=O HLIBNTOXKQCYMV-UHFFFAOYSA-N 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000009594 systemic scleroderma Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- FWOBBEOKTITUHK-UHFFFAOYSA-N tert-butyl N-benzylcarbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC=C1 FWOBBEOKTITUHK-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 201000004420 transitional papilloma Diseases 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N β-glycerophosphoric acid Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
Abstract
Disclosed is the use of BUBR1 as a biomarker for predicting the response to a compound, wherein the compound is a compound of general formula I (see abstract drawing) wherein - R represents phenyl, thienyl or pyridinyl - wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; - and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; - X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by hydroxy or lower alkoxy; - R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; - R2, R3 and R6 represent hydrogen; - R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower alkoxy; - or R4 and R5 together represent methylenedioxy; - and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of prodrugs thereof; - or wherein - R represents phenyl or pyridinyl - wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; - and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; - X represents oxygen; - R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; - R2, R3 and R6 represent hydrogen; - R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower alkoxy; - or R4 and R5 together represent methylenedioxy; - and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of prodrugs thereof, - and wherein the prefix lower denotes a radical having up to and including a maximum of 7 carbon atoms, and wherein the response is of a disease in a subject and the biomarker BUBR1 is measured ex vivo in a sample or samples taken from the human or animal body. ntly selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; - and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; - X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by hydroxy or lower alkoxy; - R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; - R2, R3 and R6 represent hydrogen; - R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower alkoxy; - or R4 and R5 together represent methylenedioxy; - and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of prodrugs thereof; - or wherein - R represents phenyl or pyridinyl - wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; - and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; - X represents oxygen; - R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; - R2, R3 and R6 represent hydrogen; - R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower alkoxy; - or R4 and R5 together represent methylenedioxy; - and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of prodrugs thereof, - and wherein the prefix lower denotes a radical having up to and including a maximum of 7 carbon atoms, and wherein the response is of a disease in a subject and the biomarker BUBR1 is measured ex vivo in a sample or samples taken from the human or animal body.
Description
Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles
The present invention relates to use of BUBR1 as a biomarker for predicting
the response of a disease, such as a neoplastic or autoimmune disease, preferably
cancer, to a compound of general formula I, such as 3-(4-{1-[2-(4-amino-phenyl)
oxo-ethyl]-1H-benzoimidazolyl}-furazanylamino)-propionitrile (BAL27862). In
other aspects it relates to methods and kits, as well as methods of treatment
involving the use of the biomarker.
Microtubules are one of the components of the cell cytoskeleton and are
composed of heterodimers of alpha and beta tubulin. Agents that target microtubules
are among the most effective cytotoxic chemotherapeutic agents having a broad
spectrum of activity. Microtubule destabilising agents (e.g. the vinca-alkaloids such
as vincristine, vinblastine and vinorelbine) are used for example in the treatment of
several types of hematologic malignancies, such as lymphoblastic leukaemia and
lymphoma, as well as solid tumours, such as lung cancer. Microtubule stabilising
agents (e.g. the taxanes such as paclitaxel, docetaxel) are used for example in the
treatment of solid tumours, including breast, lung and prostate cancer.
However resistance to these known microtubule targeting agents can occur.
The resistance can either be inherent or can be acquired after exposure to these
agents. Such resistance therefore impacts patient survival rates, as well as choices
of treatment regimes. Several potential mechanisms of resistance have been
identified, and include defects in the microtubule targets, such as elevated levels of
beta-tubulin subtype III and acquired mutations in beta-tubulin subtype I that are
known to reduce taxane binding. Furthermore, defects in other cell proteins have
been suggested to be associated with resistance to certain microtubule targeting
agents, such as overexpression of p-glycoprotein (P-gp pump, also known as multi-
drug resistance protein 1 or MDR1). Such factors may then be used as biomarkers of
resistance to these conventional microtubule targeting agents.
A relatively recently discovered class of microtubule destabilising agents are
compounds encompassed by the formula given below:
wherein
R represents phenyl, thienyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are
methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by
hydroxy or lower alkoxy;
R represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
2 3 6
R , R and R represent hydrogen;
R and R , independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R and R together represent methylenedioxy;
and pharmaceutically acceptable salts thereof;
or wherein
R represents phenyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent
substituents are methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents oxygen;
R represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
2 3 6
R , R and R represent hydrogen;
R and R , independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R and R together represent methylenedioxy;
and pharmaceutically acceptable salts thereof;
and wherein the prefix lower denotes a radical having up to and including a maximum
of 7, especially up to and including a maximum of 4 carbon atoms.
These compounds are disclosed in WO2004/103994 A1, which is
incorporated by cross-reference herein. These compounds have been shown to
arrest tumour cell proliferation and induce apoptosis.
The synthesis of compounds of formula I is described in WO2004/103994
A1, in general on pages 29-35, and specifically on pages 39-55, which are
incorporated herein by cross-reference. They may be prepared as disclosed or by an
analogous method to the processes described therein.
One compound falling within this class, known as BAL27862, and shown in
WO2004/103994 A1 as example 58, and specifically incorporated by reference
herein, has the structure and chemical name given below:
Chemical name:
3-(4-{1-[2-(4-Amino-phenyl)oxo-ethyl]-1H-benzoimidazolyl}-furazanylamino)-
propionitrile;
or herein as Compound A.
Further compounds exemplified in WO2004/103994 A1 as examples 50 and
79 respectively, and also specifically incorporated by cross-reference herein, have
the structures and chemical names given below:
Chemical name: 2-[2-(4-Amino-furazanyl)-benzoimidazolyl](4-amino-phenyl)-
ethanone;
or herein as Compound B,
and
Chemical name: 3-(4-{1-[2-(6-Amino-pyridinyl)oxo-ethyl]-1H-
benzoimidazolyl}-furazanylamino)-propionitrile;
or herein as Compound C.
BAL27862 has demonstrated activity across a broad panel of experimental,
solid tumour xenograft models. Moreover, activity was retained even against tumour
models which were selected for resistance to conventional microtubule targeting
agents (including the vinca-alkaloid microtubule destabilisers and the microtubule
stabilisers paclitaxel and epothilone B). BAL27862 activity was not affected by over-
expression of the P-gp pump in any models tested in vitro, nor in human mammary
tumour xenografts. Additionally, BAL27862 retained its activity despite elevated
levels of beta-tubulin subtype III and mutations in tubulin subtype I.
Hence, BAL27862 activity is not affected by a number of factors that confer
resistance to conventional microtubule targeting agents.
Moreover, it is known that compounds of general formula I have a different
effect on the phenotype of cells compared to other microtubule targeting agents,
including other microtubule destabilisers. Treatment with a compound of general
formula I induces a consistent microtubule phenotype in tumour cell lines derived
from a variety of organs, for example lung, cervix and breast, as seen in Figure 1.
Staining the microtubules in these cells with an anti-alpha-tubulin antibody shows
that rather than the mitotic spindle fibres of untreated cells, only dot-like structures
are visible in the treated cells. This same effect is also shown using Compounds C
and B in Figures 2A and 2B respectively on the lung cancer cell line A549. It is
however very distinct from that observed with the conventional microtubule targeting
agents vinblastine, colchicine, paclitaxel and nocodazole as seen in Figures 3B, 3C,
3D and 4, respectively. The microtubules were stained with an anti-alpha-tubulin
antibody and the cells viewed at a 1000 x magnification (Figures 3, 4). For the cells
treated with BAL27862, multiple dot-like structures are visible, whereas, in stark
contrast, the other conventional drugs produce filamentous microtubule structures, or
dense microtubule aggregate structures. These differences at the phenotypic level, at
compound doses considered optimal in terms of antiproliferative effect, indicate a
difference in the mode of action at the molecular level.
Furthermore, it is known that BAL27862 elicits a dominant microtubule
phenotype in the presence of the other microtubule targeting agents. Treatment with
vinblastine, colchicine, paclitaxel or nocodazole alone induced the microtubule
phenotypes characteristic of these agents (Figure 5A, 5D, 5G, 6C-6F respectively).
However, combination treatment with BAL27862 for the last 4 hours resulted in
disruption of these phenotypes; despite the continued presence of vinblastine,
colchicine, paclitaxel, or nocodazole (Figure 5B, 5E, 5H, 6G-6J respectively). In
contrast, treating first with BAL27862 and subsequently for 4 hours in combination
with vinblastine, colchicine, paclitaxel or nocodazole had no impact on generation of
the phenotype consistent with BAL27862 treatment (Figure 5C, 5F, 5I, 6K-6N
respectively).
These data all demonstrate that BAL27862 affects microtubule biology in a
different manner than conventional microtubule targeting agents.
Thus, from information about conventional microtubule targeting agents,
predictions cannot be made concerning if, or how, particular genes are involved in
the action of compounds of formula I.
An object of the present invention is to identify factors which are associated
with response to compounds of formula I or pharmaceutically acceptable derivatives
thereof, for example to identify factors associated with resistance to compounds of
general formula I, in particular BAL27862 or pharmaceutically acceptable derivatives
thereof, as defined below; and/or to provide the public with a useful choice
It has surprisingly been found that BUBR1 may be used as a biomarker of
response to treatment with a compound of general formula I or pharmaceutically
acceptable derivatives thereof, as defined below.
In one preferred embodiment described herein, relatively low BUBR1 levels
in a sample are associated with inherent and acquired resistance to BAL27862, as
described below.
BUBR1 has been assigned Human Gene Nomenclature Committee
Identification number HGNC ID:1149 and Entrez Gene ID 701. A sequence
corresponding to human BUBR1 is available via National Center for Biotechnology
Information (NCBI) reference number NP_001202 (Figure 18, SEQ ID No. 1,
NP_001202.4).
BUBR1 is also known as hBUBR1 and BubR1; Budding uninhibited by
benzimidazoles 1, S. cerevisiae, homolog, beta; mitotic checkpoint gene BUB1B;
BUB1B; BUB1 beta; mitotic checkpoint kinase Mad3L; MAD3L; MAD3-like protein
kinase; and SSK1. The name BUB1B is commonly associated with the nucleic acid
sequence, while publications focusing on the protein have commonly used the term
BUBR1. For simplicity, the term BUBR1 shall be used herein to encompass all the
above mentioned synonyms and shall refer to this entity on both the nucleic acid and
protein levels as appropriate.
The name budding uninhibited by benzimidazoles was assigned to the yeast
homolog by Hoyt et al. after experiments conducted with benomyl. (Hoyt MA. et al.,
S. Cerevisiae Genes Required for Cell Cycle Arrest in Response to Loss of
Microtubule Function. Cell, Vol. 66, 507-517, Aug. 9, 1991) This publication
describes mutations in the bub yeast homolog that resulted in hypersensitivity to
benomyl.
The human homologue is located on chromosome 15q15. The sequence of
the human BUBR1 gene was published in US 6,593,098 B1 and is identified therein
as human BUB1A. Example VI of that patent describes an experiment performed in
HeLa cells, wherein the activity of endogenous BUB1A (BUBR1) was inhibited by
microinjection of anti-huBUB1A antibodies. The injected cells were then tested for
their ability to remain arrested in mitosis when exposed to nocadozole, a microtubule
destabiliser. The patent states that the cells injected with huBUB1a antibodies failed
to arrest in mitosis in the presence of nocodazole and proceeded to undergo
apoptosis as a result of premature exit from mitosis.
Similarly to the Hoyt publication, this suggests that loss of BUBR1 function in
cells which are then treated with nocodazole results in a heightened rate of
apoptosis.
However, in contrast, the present inventors have found that loss of BUBR1
expression is associated with lowered levels of cell death in response to compounds
of general formula I, i.e. resistance to these compounds. It is again to be emphasized
that compounds of formula I have a different effect on the phenotype of cells
compared to other microtubule agents, including other microtubule destabilisers, as
seen in Figures 3, 4, 5 and 6. The discrepancy between the findings of, on the one
side US 6,593,098 B1 and Hoyt, and on the other side, the present inventors,
confirms that predictions from information concerning conventional microtubule
agents cannot be made concerning if, or how, particular genes are involved in the
activity of compounds of general formula I.
In a first aspect, the invention provides a use of BUBR1 as a biomarker for
predicting the response to a compound, wherein the compound is a compound of
general formula I
wherein
R represents phenyl, thienyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are
methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by
hydroxy or lower alkoxy;
R represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
2 3 6
R , R and R represent hydrogen;
R and R , independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R and R together represent methylenedioxy;
and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of
prodrugs thereof;
or wherein
R represents phenyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent
substituents are methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents oxygen;
R represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
2 3 6
R , R and R represent hydrogen;
R and R , independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R and R together represent methylenedioxy;
and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and
salts of prodrugs thereof,
and wherein the prefix lower denotes a radical having up to and including a
maximum of 7 carbon atoms, and wherein the response is of a disease in a subject
and the biomarker BUBR1 is measured ex vivo in a sample or samples taken from
the human or animal body.
In a second aspect, the invention provides a method for predicting in a
subject suffering of a cancer the response of that cancer to a compound of general
formula I or to a pharmaceutically acceptable salt, solvate, polymorph, prodrug or salt
of prodrug thereof as defined in the invention, comprising the steps of:
a) measuring ex vivo a level of BUBR1 in a sample pre-obtained from tumour
tissue or circulating tumour cells of the subject to obtain a value or values
representing this level; and
b) comparing the value or values from step a) to a standard value or set of
standard values from subjects with the same cancer type,
wherein a lower BUBR1 level in the sample relative to the standard value or
set of standard values is predictive of resistance of the subject's cancer to the
compound of formula (I) or to the pharmaceutically acceptable salt, solvate,
polymorph, prodrug or salt of prodrug thereof.
In a third aspect, the invention provides a use of a compound of general
formula I or of a pharmaceutically acceptable salt, solvate, polymorph, prodrug or salt
of prodrug thereof, as defined above, for the preparation of a pharmaceutical
composition for treating a cancer in a subject in need thereof, wherein the subject is
selected for treatment with the compound of general formula I or with the salt,
solvate, polymorph, prodrug or salt of prodrug thereof, as defined above, if the level
of BUBR1, measured ex vivo in a sample taken from the subject, is not lower than a
standard value or set of standard values from subjects with the same tumour
histotype or from normal cells, tissue or body fluid.
In a fourth aspect, the invention provides a kit when used for predicting the
response to a compound of general formula I or a pharmaceutically acceptable salt,
solvate, polymorph, prodrug or salt of prodrug thereof, as defined above, comprising
reagents necessary for measuring a level of BUBR1 in a sample taken from a sample
of a subject with a cancer, and further comprising a comparator module which
comprises a standard value or set of standard values of a level of BUBR1 taken from
samples of tumour tissue or circulating tumour cells of subjects with a cancer of the
same histotype to which the level of BUBR1 in the sample is compared.
Also described is a use of BUBR1 as a biomarker for predicting the response
to a compound, wherein the compound is a compound of general formula I
wherein
R represents phenyl, thienyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are
methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by
hydroxy or lower alkoxy;
R represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
2 3 6
R , R and R represent hydrogen;
R and R , independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R and R together represent methylenedioxy;
and pharmaceutically acceptable derivatives thereof,
or wherein
R represents phenyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent
substituents are methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents oxygen;
R represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
2 3 6
R , R and R represent hydrogen;
R and R , independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R and R together represent methylenedioxy;
and pharmaceutically acceptable derivatives thereof;
and wherein the prefix lower denotes a radical having up to and including a maximum
of 7, especially up to and including a maximum of 4 carbon atoms.
Preferably the response may be of a disease in a subject. Also preferably
the response may be to treatment, i.e. to treatment with the compound of general
formula I or pharmaceutically acceptable derivatives thereof.
The biomarker BUBR1 is measured ex vivo in a sample or samples taken
from the human or animal body, preferably taken from the human body.
Also described is a use of BUBR1 as a biomarker for predicting the
resistance of a disease in a subject to a compound of general formula I or
pharmaceutically acceptable derivatives thereof as defined above.
Preferably the pharmaceutically acceptable derivative is selected from the
group consisting of a salt, solvate, pro-drug, salt of a pro-drug, polymorph and isomer
of a compound of general formula I as defined above. Pro-drugs are preferably ester
and amides of naturally occurring amino acids, small peptides or pegylated hydroxy
acids. More preferably, the pro-drug is an amide formed from an amino group
present within the R group of the compound of general formula I and the carboxy
group of glycine, alanine or lysine.
Particularly preferably the compound is
or a pharmaceutically acceptable salt thereof, preferably a
hydrochloride salt thereof , most preferably a dihydrochloride salt thereof.
Also described is a method for predicting the response of a disease in a
subject to a compound of general formula I or pharmaceutically acceptable
derivatives thereof as defined above, comprising the steps of:
a) measuring a level of BUBR1 in a sample pre-obtained from the subject to
obtain a value or values representing this level; and
b) comparing the value or values from step a) to a standard value or set of
standard values.
Further preferably the response which is predicted is resistance.
The measuring of a level or levels of BUBR1 is performed ex-vivo in a
sample or samples pre-obtained from the subject. Pre-obtained refers to the fact that
the sample is obtained before it is subjected to any method involving measuring the
level of the biomarker, and pre-obtained is not to be understood as in relation to
treatment.
In a preferred embodiment, a lower level of BUBR1 in the sample from the
subject relative to the standard value or set of standard values predicts resistance.
Also preferably, the disease is a neoplastic or autoimmune disease. More
preferably the disease is cancer. Especially preferably, the cancer is selected from
the group consisting of breast cancer, prostate cancer, cervical cancer, ovarian
cancer, gastric cancer, colorectal cancer (i.e including colon cancer and rectal
cancer), pancreatic cancer, liver cancer, brain cancer, neuroendocrine cancer, lung
cancer, kidney cancer, hematological malignancies, melanoma and sarcomas. More
especially preferably the cancer is selected from the group consisting of breast
cancer, cervical cancer, ovarian cancer, gastric cancer, pancreatic cancer, colon
cancer and lung cancer. More particularly preferably the cancer is selected from the
group consisting of cervical cancer, ovarian cancer, gastric cancer, pancreatic
cancer, colon cancer and lung cancer. In another particularly preferred embodiment,
wherein acquired resistance is determined, the cancer is lung cancer or ovarian
cancer. In yet another particularly preferred embodiment, wherein inherent resistance
is determined, the cancer is selected from the group consisting of cervical cancer,
breast cancer, ovarian cancer, gastric cancer, pancreatic cancer, colon cancer and
lung cancer, more preferably lung cancer or gastric cancer.
Also described is a method of treating a neoplastic or autoimmune disease,
preferably cancer, in a subject in need thereof, comprising measuring a level of
BUBR1 in a sample from the subject to obtain a value or values representing this
level, and treating the subject with a compound of general formula I or a
pharmaceutically acceptable derivative thereof as defined above, if the level of
BUBR1 in said sample is not lower than a standard value or set of standard values.
Also described is a BUBR1 for use in the treatment of a neoplastic or
autoimmune disease, preferably cancer, comprising measuring a level of BUBR1 in a
sample from the subject to obtain a value or values representing this level, and
treating the subject with a compound of general formula I or a pharmaceutically
acceptable derivative thereof as defined above, if the level of BUBR1 is not lower
than a standard value or set of standard values.
The measuring of a level of BUBR1 is performed ex-vivo in a sample pre-
obtained from the subject.
Also described is a method of treating a neoplastic or autoimmune disease,
preferably cancer, by first increasing the level of BUBR1 in a subject that has a
sample with a lower level of BUBR1 compared to a standard level or set of standard
levels, then treating the subject with a compound of general formula I or a
pharmaceutically acceptable derivative thereof as defined above.
Also described is a kit for predicting the response to a compound of general
formula I or a pharmaceutically acceptable derivative thereof, as defined above,
comprising reagents necessary for measuring the level of BUBR1 in a sample. More
preferably the kit also comprises a comparator module which comprises a standard
value or set of standard values to which the level of BUBR1 in the sample is
compared.
Furthermore preferably the kit comprises a compound of general formula I or
a pharmaceutically acceptable derivative thereof as defined above. In an especially
preferred embodiment the kit comprises a compound of the following formula or a
pharmaceutically acceptable salt thereof:
chemical name: S-2,6-Diamino-hexanoic acid [4-(2-{2-[4-(2-cyano-
ethylamino)-furazanyl]-benzoimidazolyl}-acetyl)-phenyl]-amide
In a particularly preferred embodiment the pharmaceutically acceptable salt
is a dihydrochloride salt.
Also described is a device for predicting the response to a compound of
general formula I or a pharmaceutically acceptable derivative thereof as defined
above, comprising reagents necessary for measuring the level of BUBR1 in a sample
and a comparator module which comprises a standard value or set of standard
values to which the level of BUBR1 in the sample is compared.
In a preferred embodiment, the reagents in the kit or device comprise a
capture reagent comprising a detector for BUBR1, and a detector reagent. Especially
preferably the capture reagent is an antibody. Also preferably, the disease is
predicted to be resistant to treatment with said compound when BUBR1 is lower
relative to a standard value or set of standard values. In a preferred embodiment, the
comparator module is included in instructions for use of the kit. In another preferred
embodiment the comparator module is in the form of a display device.
Embodiments of the present invention will now be described by way of
example with reference to the accompanying figures. The invention however is not to
be understood as limited to these embodiments.
Brief Description of the Figures
Figure 1: Shows the treatment of human tumour cell lines from different
histotypes with 50 nM BAL27862. The microtubules of mitotic or G2/M arrested cells
were stained after 24 hours treatment with 50 nM BAL27862 or vehicle control.
Fig. 1A and 1B: A549 NSCLC cells;
Fig. 1C and 1D: HeLa cervical cancer cells;
Fig. 1E and 1F: SKBR3 breast cancer cells
Vehicle control treatment: Figures 1A, 1C & 1E,
BAL27862 treatment: Figures 1B, 1D & 1F.
Figure 2: Shows the treatment of A549 NSCLC cells with the Compounds B
and C. The microtubules of mitotic or G2/M arrested A549 NSCLC cells were stained
after 24 hours treatment with 80 nM or 20 nM of Compounds B and C, respectively.
The white scale bar represents 10 micrometres.
Fig. 2A: treatment with 20 nM Compound C
Fig. 2B: treatment with 80 nM Compound B
Figure 3: Shows a comparison of treatment of cells with BAL27862
compared to conventional microtubule targeting agents. Microtubules of mitotic or
G2/M arrested A549 NSCLC cells were stained after 24 hours of treatment with 50
nM of A: BAL27862; B: vinblastine; C: colchicine; D: paclitaxel. Stacks of images
taken every 1 µm were processed by using ImageJ software.
Figure 4: Shows a comparison of treatment of A549 NSCLC cells with
BAL27862 compared to nocodazole. Microtubules of mitotic or G2/M arrested cells
were stained after 24 h of treatment with various concentrations of nocodazole (B, C
& D) and BAL27862 (E, F & G). A: control, B: Nocodazole 50 nM, C: Nocodazole
100 nM, D: Nocodazole 200 nM, E: BAL27862 20 nM; F: BAL27862 30 nM and G:
BAL27862 50 nM. The white scale bar represents 10 micrometres. Representative
images of the microtubule phenotypes observed are shown.
Figure 5: Shows a combination of treatment with BAL27862 and
conventional microtubule-targeting agents. Microtubules of mitotic or G2/M arrested
A549 NSCLC cells were stained after treatment for the times indicated below. 50 nM
BAL27862, 50 nM vinblastine, 50 nM colchicine and 25 nM paclitaxel were used. The
white scale bar represents 10 micrometres.
Fig. 5A: 24 hours vinblastine treatment;
Fig. 5B: 24 hours vinblastine treatment with the final 4 hours including
BAL27862;
Fig. 5C: 24 hours BAL27862 treatment with the final 4 hours including
vinblastine.
Fig. 5D: 24 hours colchicine treatment;
Fig. 5E: 24 hours colchicine treatment with the final 4 hours including
BAL27862;
Fig. 5F: 24 hours BAL27862 treatment with the final 4 hours including
colchicine.
Fig. 5G: 24 hours paclitaxel treatment;
Fig. 5H: 24 hours paclitaxel treatment with the final 4 hours including
BAL27862;
Fig. 5I: 24 hours BAL27862 treatment with the final 4 hours including
paclitaxel.
Figure 6: Shows a combination of treatment with BAL27862 and
nocodazole. Microtubules of mitotic or G2/M arrested A549 NSCLC cells were
stained after treatment for the times indicated below. 25 nM BAL27862 and
nocodazole at the concentrations indicated below were used. The white scale bar
represents 10 micrometers.
Fig. 6A: 24 hours control treatment;
Fig. 6B: 24 hours of 25 nM BAL27862 treatment;
Fig. 6C: 24 hours of 50 nM nocodazole treatment
Fig. 6D: 24 hours of 100 nM nocodazole treatment
Fig. 6E: 24 hours of 150 nM nocodazole treatment
Fig. 6F: 24 hours of 200 nM nocodazole treatment
Fig. 6G: 24 hours of 50 nM nocodazole treatment with the final 4 hours
including 25 nM BAL27862;
Fig. 6H: 24 hours of 100 nM nocodazole treatment with the final 4 hours
including 25 nM BAL27862;
Fig. 6I: 24 hours of 150 nM nocodazole treatment with the final 4 hours
including 25 nM BAL27862;
Fig. 6J: 24 hours of 200 nM nocodazole treatment with the final 4 hours
including 25 nM BAL27862;
Fig. 6K: 24 hours of 25 nM BAL27862 treatment with the final 4 hours
including 50 nM nocodazole;
Fig. 6L: 24 hours of 25 nM BAL27862 treatment with the final 4 hours
including 100 nM nocodazole;
Fig. 6M: 24 hours of 25 nM BAL27862 treatment with the final 4 hours
including 150 nM nocodazole;
Fig. 6N: 24 hours of 25 nM BAL27862 treatment with the final 4 hours
including 200 nM nocodazole.
Figure 7: Shows immunoblot analysis of BUBR1 expression after
transfection with a BUBR1 siRNA pool. Control: non-transfected cells treated with
medium alone; Lipofectamine: cells treated with transfection reagent alone; NTC:
cells treated with non-targeting control siRNA; BUBR1: cells treated with a BUBR1-
specific siRNA pool. Alpha-tubulin levels act as a loading control. Cell Signaling (CS)
or BD Transduction Laboratories (BD) BUBR1 antibodies were used as indicated.
Fig. 7A: HeLa cervical cancer cells, Fig. 7B: H460 lung cancer cells
Figure 8: Effect of a BUBR1 siRNA pool on response to BAL27862 in HeLa
cells. HeLa cells were seeded and treated with siRNA. After 48 hours incubation, the
cells were treated with DMSO alone or 50 nM BAL27862 for 24 hours before
analysis. Upper panel: Histogram of the fraction of cells per well (in %) displaying the
untreated phenotype. Lower panel: Histogram of the number of cells per well. Error
bars: Standard deviation. Negative control: non-targeting control siRNA. BubR1:
BUBR1-specific siRNA pool treated cells.
Figure 9: Shows the effect of a BUBR1 siRNA pool on response of HeLa
cells to BAL27862. Exponentially growing HeLa cells were treated with medium alone
(control), or transfected with lipofectamine, non-targeting control (NTC) siRNA or a
BUBR1-specific siRNA pool. After 24 hours, BAL27862 was added at the indicated
concentrations, with DMSO vehicle used as a control. After 48 hours treatment,
effects on HeLa cell proliferation (Fig. 9A) and viability (Fig. 9B) were assessed using
the YO-PRO proliferation assay. a.u = data is expressed as arbitrary units
Figure 10: Shows the effect of a BUBR1 siRNA pool on response of H460
cells to BAL27862. Exponentially growing H460 cells were transfected with non-
targeting control (NTC) siRNA or a BUBR1-specific siRNA pool. After 24 hours,
BAL27862 was added at the indicated concentrations, with DMSO vehicle used as a
control. After 48 hours treatment, effects on H460 cell proliferation (Fig. 10A) and
viability (Fig. 10B) were assessed using the YO-PRO proliferation assay. a.u = data
is expressed as arbitrary units
Figure 11: Shows the effect of a BUBR1 siRNA pool on response of MCF-7
cells to BAL27862. Exponentially growing MCF-7 cells were treated with non-
targeting control (NTC) siRNA or a BUBR1-specific siRNA pool. After 24 hours,
BAL27862 was added at the indicated concentrations, with DMSO vehicle used as a
control. After 48 hours treatment, effects on MCF-7 cell proliferation (Fig. 11A) and
viability (Fig. 11B) were assessed using the YO-PRO proliferation assay. a.u = data
is expressed as arbitrary units
Figure 12: Shows the effect of a BUBR1 siRNA pool on response of HeLa,
Panc1 and HCT116 cells to BAL27862. Exponentially growing cells were treated with
non-targeting control (NTC) siRNA or a BUBR1-specific siRNA pool. After 24 hours,
50 nM (HeLa, HCT116) or 30 nM (Panc1) BAL27862 was added, with DMSO vehicle
used as a control. After 48 hours treatment, effects on HeLa (Fig. 12A), Panc1 (Fig.
12B) and HCT116 (Fig. 12C) cell proliferation were assessed using the Crystal Violet
assay. a.u = data is expressed as arbitrary units.
Figure 13: Shows the effect of individual BUBR1 siRNAs on response of
HeLa cells to BAL27862. Exponentially growing cells were treated with non-targeting
control (NTC) siRNA or individual BUBR1-specific siRNAs (siRNA #1, 2, 3 and 4, as
defined in the experimental methodology section below). After 24 hours, 50 nM
BAL27862 was added, with DMSO vehicle used as a control. After 48 hours
treatment, effects on HeLa cell proliferation (Fig. 13A) were assessed using the
Crystal Violet assay and effects on BUBR1 protein expression were assessed by
immunoblotting (Fig 13B). a.u = data is expressed as arbitrary units.
Figure 14: Shows that BUBR1 protein levels decrease in tumour lines with
acquired resistance to BAL27862. Tumour cell lines were selected for resistance to
BAL27862 through in vitro cultivation in the presence of BAL27862. Based on IC
determinations, BAL27862 resistance factors versus parental lines were: A549 (3.0
fold); SKOV3 (7.6 fold – resistant 1 line); H460 (5.3 fold)(see Table 1). Whole cell
protein extracts were prepared from parental and resistant lines and analysed by
immunoblot for BUBR1 expression. Actin levels act as a loading control.
Figure 15: Shows that decreased BUBR1 protein levels are maintained in
the SKOV3 tumour line during resistance development. SKOV3 tumour cells were
selected for resistance to BAL27862 through in vitro cultivation in the presence of
BAL27862 for increasing time periods. Based on IC determinations, BAL27862
resistance factors versus parental lines were: SKOV3 resistant 1 (7.6 fold), SKOV3
resistant 2 (11.6 fold)(see Table 1). Whole cell protein extracts were prepared from
parental and resistant lines and analysed by immunoblot for BUBR1 expression
using the BD Transduction Laboratories (BD) BUBR1 antibody. Alpha-tubulin levels
act as a loading control.
Figure 16: Shows that tumour cell BUBR1 levels are decreased in patient-
derived xenografted tumours defined as BAL27862 resistant by ex vivo colony
outgrowth analysis. Patient-derived tumour xenografts (maintained in nude mice)
were prepared, fixed and stained for BUBR1 protein expression using
immunohistochemistry. BAL27862, paclitaxel and vinblastine resistance and
sensitivity is as defined in Table 2.
Figure 17: Shows that for BUBR1, protein levels in tumour cells are reflected
by its RNA expression levels. Figure 17A: Samples were prepared from HeLa and
H460 cell lines, and quantitative RT-PCR was performed on these to measure RNA
levels. The HeLa results were set at 100 %, and the graph shows the RNA
expression levels in the H460 sample relative to the HeLa values. Figure 17B: Whole
cell protein extracts were prepared from the same passages of the HeLa and H460
cell lines and then analysed by immunoblotting using BD Transduction Laboratories
(BD) BUBR1 antibodies for BUBR1 protein expression. Alpha-tubulin levels act as a
loading control.
Figure 18: Shows preferred protein sequence of BUBR1 (SEQ. ID No. 1)
Figure 19: Shows preferred nucleic acid sequence of BUBR1 (SEQ. ID No.
Detailed Description
Compounds of general formula I
The compounds described herein are represented by general formula I:
wherein
R represents phenyl, thienyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are
methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by
hydroxy or lower alkoxy;
R represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
2 3 6
R , R and R represent hydrogen;
R and R , independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R and R together represent methylenedioxy;
and pharmaceutically acceptable derivatives thereof,
or wherein
R represents phenyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent
substituents are methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents oxygen;
R represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
2 3 6
R , R and R represent hydrogen;
R and R , independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R and R together represent methylenedioxy;
and pharmaceutically acceptable derivatives thereof;
and wherein the prefix lower denotes a radical having up to and including a maximum
of 7, especially up to and including a maximum of 4 carbon atoms.
Heterocyclyl designates preferably a saturated, partially saturated or
unsaturated, mono- or bicyclic ring containing 4-10 atoms comprising one, two or
three heteroatoms selected from nitrogen, oxygen and sulfur, which may, unless
otherwise specified, be carbon or nitrogen linked, wherein a ring nitrogen atom may
optionally be substituted by a group selected from lower alkyl, amino-lower alkyl, aryl,
aryl-lower alkyl and acyl, and a ring carbon atom may be substituted by lower alkyl,
amino-lower alkyl, aryl, aryl-lower alkyl, heteroaryl, lower alkoxy, hydroxy or oxo.
Examples of heterocyclyl are pyrrolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl,
morpholinyl, piperazinyl, dioxolanyl and tetrahydropyranyl.
Acyl designates, for example, alkylcarbonyl, cyclohexylcarbonyl,
arylcarbonyl, aryl-lower alkylcarbonyl, or heteroarylcarbonyl. Lower acyl is preferably
lower alkylcarbonyl, in particular propionyl or acetyl.
Preferably, the compound of general formula I according to the invention is
defined as wherein R is selected from the group consisting of hydrogen, acetyl,
CH CH CN and CH CH CH OH.
2 2 2 2 2
In one preferred embodiment, the compound of general formula I according
to the invention is selected from the group consisting of:
4-(1-Phenacyl-1H-benzimidazolyl)-furazanylamine,
4-[1-(4-Bromophenacyl)-1H-benzimidazolyl]-furazanylamine oxime,
N-{4-[1-(4-Chlorophenacyl)-1H-benzimidazolyl]-furazanyl}-acetamide,
4-[1-(4-Chlorophenacyl)-1H-benzimidazolyl]-furazanyl-N-(2-cyanoethyl)-amine
4-[1-(4-Chlorophenacyl)-1H-benzimidazolyl]-furazanyl-N-(3-hydroxypropyl)-
amine,
4-[1-(3-Aminochlorophenacyl)-1H-benzimidazolyl]-furazanylamine
4-[1-(3-Methoxymethoxymethoxy-phenacyl)-1H-benzimidazolyl]-furazan
ylamine,
and pharmaceutically acceptable derivatives thereof.
In another preferred embodiment, the compound of general formula I
according to the invention is:
wherein
R, Y and R are defined as follows :
R Y R
NOH H
NOMe H
NOH H
NOH H
NOMe H
NOH H
NOMe H
NOH H
NOMe H
NOMe H
Cl Cl
NOH H
NOMe H
NOH H
NOMe H
NOMe H
Et N
O Ac
O CH CH CN
O CH CH CN
O CH CH CH OH
2 2 2
O CH CH CN
O CH CH CN
O CH CH CN
O CH CH CN
AcNH
AcHN
O CH CH CN
HN N
O CH CH CN
HN N
O CH CH CN
MeO N
or pharmaceutically acceptable derivatives thereof.
In yet another preferred embodiment, the compound of general formula I
according to the invention is selected from the group consisting of:
4-(1-Phenoxymethyl-1H-benzimidazolyl)-furazanylamine,
4-[1-(4-Fluorophenoxymethyl)-1H-benzimidazolyl]-furazanylamine,
4-[1-(3,4-Dimethylphenoxymethyl)-1H-benzimidazolyl]-furazanyl-N-(2-
cyanoethyl)-amine,
and compounds represented by the formula:
wherein R and R are as defined below
CH CH CN
CH CH CN
CH CH CN
CH CH CN
CH CH CH OH
2 2 2
Cl N
HN N
or pharmaceutically acceptable derivatives thereof.
In still yet another preferred embodiment the compound of general formula I
according to the invention is:
wherein R, R and R are as defined below
R R R
Me Me
Me Me
Me Me
Me Me
Me Me
OMe OMe
OMe OMe
OMe OMe
OMe OMe
OMe OMe
or pharmaceutically acceptable derivatives thereof.
More preferably, the compound described herein is a compound of general
formula I
wherein
R represents phenyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
selected from lower alkyl, lower alkoxy, amino, acetylamino, halogen and nitro;
and wherein pyridinyl is optionally substituted by amino or halogen;
X represents a group C=O;
R represents hydrogen or cyano-lower alkyl;
2 3 4 5 6
R , R , R , R and R represent hydrogen;
and pharmaceutically acceptable derivatives thereof,
and wherein the prefix lower denotes a radical having up to and including a maximum
of 7, especially up to and including a maximum of 4 carbon atoms.
Especially preferably, the compound described herein is represented by the
following formula
wherein R, Y and R are defined as follows :
R Y R
O CH CH CN
H N N
O CH CH CN
H N N
or pharmaceutically acceptable derivatives thereof.
More especially preferably, the compound described herein is represented
by the following formula
wherein R, Y and R are defined as follows:
R Y R
O CH CH CN
O CH CH CN
HN N
or pharmaceutically acceptable derivatives thereof.
Particularly preferably, the compound according to the invention is
or pharmaceutically acceptable derivatives thereof.
The term derivative or derivatives in the phrase “pharmaceutically
acceptable derivative” or “pharmaceutically acceptable derivatives” of compounds of
general formula I relates to salts, solvates and complexes thereof and to solvates
and complexes of salts thereof, as well as to pro-drugs, polymorphs, and isomers
thereof (including optical, geometric and tautomeric isomers) and also salts of pro-
drugs thereof. In a more preferred embodiment, it relates to salts and pro-drugs, as
well as to salts of pro-drugs thereof.
Salts are preferably acid addition salts. Salts are formed, preferably with
organic or inorganic acids, from compounds of formula (I) with a basic nitrogen atom,
especially the pharmaceutically acceptable salts. Suitable inorganic acids are, for
example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic
acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid,
dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid,
pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino
acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid,
methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic
acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic
acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid,
ethane-1,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1,5-
naphthalene-disulfonic acid, 2-, 3- or 4-methylbenzenesulfonic acid, methylsulfuric
acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexylsulfamic acid, N-methyl-, N-
ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic
acid.
The compound described herein may be administered in the form of a pro-
drug which is broken down in the human or animal body to give a compound of the
formula I. Examples of pro-drugs include in vivo hydrolysable esters and amides of a
compound of the formula I. Particular pro-drugs considered are ester and amides of
naturally occurring amino acids and ester or amides of small peptides, in particular
small peptides consisting of up to five, preferably two or three amino acids as well as
esters and amides of pegylated hydroxy acids, preferably hydroxy acetic acid and
lactic acid. Pro-drug esters are formed from the acid function of the amino acid or the
C terminal of the peptide and suitable hydroxy group(s) in the compound of formula I.
Pro-drug amides are formed from the amino function of the amino acid or the N
terminal of the peptide and suitable carboxy group(s) in the compound of formula I, or
from the acid function of the amino acid or the C terminal of the peptide and suitable
amino group(s) in the compound of formula I. Particularly preferably the pro-drug
amides are formed from the amino group(s) present within the R group of formula I.
More preferably, the pro-drug is an amide formed from an amino group
present within the R group of the compound of general formula I as defined above
and the carboxy group of glycine, alanine or lysine.
Even more preferably the compound of general formula I is in the form of a
pro-drug selected from the compounds of formulae:
2 NH HN
, , ,
N N N
2 NH HN
, , ,
2 H N
N N N N
2 NH HN
, and .
In an especially preferred embodiment the compound of general formula I is
in the form of a pro-drug which has the following formula
In a most especially preferred embodiment the compound according to the
invention is
or a pharmaceutically acceptable salt thereof, preferably a hydrochloride salt, most
preferably a dihydrochloride salt.
The pharmaceutically active metabolite in vivo in this case is BAL27862.
These pro-drugs may be prepared by processes that are known per se, in
particular, a process, wherein a compound of formula (II)
(II)
wherein R is defined as for formula (I) and Z is CH or N, or a derivative of such a
compound comprising functional groups in protected form,
or a salt thereof is
(1) acylated with an amino acid of formula (III)
(III)
wherein
R is selected from hydrogen (Gly); methyl (Ala) and protected aminobutyl (Lys) and
R is a suitable amino protecting group, and
(2) any protecting groups in a protected derivative of the resulting compound are
removed to yield a pro-drug as shown above, and, if so desired,
(3) said pro-drug is converted into a salt by treatment with an acid, or a salt of a
compound of formula (II) is converted into the corresponding free compound of
formula (II) or into another salt, and/or a mixture of isomeric product compounds is
separated into the individual isomers.
Acylation of a compound of formula (II) with an amino acid of formula (III) is
performed in a manner known per se, usually in the presence of a suitable polar or
dipolar aprotic solvent, with cooling or heating as required, for example in a
temperature range from approximately minus 80°C to approximately plus 150°C,
more preferably from minus 30°C to plus 120°C, especially in a range from
approximately around 0°C to the reflux temperature of the used solvent. Optionally a
suitable base is added, in particularly an aromatic base like pyridine or collidine or a
tertiary amine base such as triethylamine or diisopropylethylamine, or an inorganic
basic salt, e.g. potassium or sodium carbonate.
Acylation may be accomplished under conditions used for amide formation
known per se in peptide chemistry, e.g. with activating agents for the carboxy group,
such as carbodiimides like N,N’-diethyl-, N,N’-dipropyl-, N,N’-diisopropyl-, N,N’-
dicyclohexylcarbodiimide and N-(3-dimethylaminoisopropyl)-N’-ethylcarbodiimide-
hydrochloride (EDC), or with agents such as 1-hydroxybenzotriazole (HOBt),
benzotriazolyloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP),
O-(7-aza-benzotriazolyl)-N,N,N’,N’-tetramethyl-uronium hexafluorophosphate
(HATU), 2-(2-oxo(2H)-pyridyl)-1,1,3,3-tetramethyluronium tetrafluoroborate
(TPTU), optionally in the presence of suitable bases, catalysts or co-reagents. The
carboxy group may also be activated as acyl halogenide, preferably as acyl chloride,
e.g. by reaction with thionylchloride or oxalylchloride, or as symmetrical or
unsymmetrical anhydride, e.g. by reaction with halogeno formates like ethyl
chloroformate, optionally in the presence of suitable bases, catalysts or co-reagents.
If one or more other functional groups, for example carboxy, hydroxy or
amino, are or need to be protected in a compound of formula (II) or (III), because
they should not take part in the reaction, these are such protecting groups as are
usually applied in the synthesis of amides like, in particular peptide compounds,
cephalosporins, penicillins, nucleic acid derivatives and sugars, which are known to
the skilled persons. Suitable protecting groups for amino groups are for example t-
butyl carbamate, benzyl carbamate or 9-fluorenylmethyl carbamate.
The protecting groups may already be present in precursors and should
protect the functional groups concerned against unwanted secondary reactions, such
as alkylations, acylations, etherifications, esterifications, oxidations, solvolysis, and
similar reactions. It is a characteristic of protecting groups that they lend themselves
readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis,
reduction, photolysis or also by enzyme activity, for example under conditions
analogous to physiological conditions, and that they are not present in the end
products. The specialist knows, or can easily establish, which protecting groups are
suitable with the reactions mentioned hereinabove and hereinafter.
The protection of such functional groups by such protecting groups, the
protecting groups themselves, and their removal reactions are described for example
in standard reference books for peptide synthesis and in special books on protective
groups such as
J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London
and New York 1973, in "Methoden der organischen Chemie" (Methods of organic
chemistry), Houben-Weyl, 4th edition, Volume 15/I, Georg Thieme Verlag, Stuttgart
1974, and in T. W. Greene, G. M. Wuts "Protective Groups in Organic Synthesis",
Wiley, New York, 2006.
Disease
The compounds of general formula I described herein have been shown to
arrest cell proliferation and induce apoptosis.
Deregulation of cell proliferation, or lack of appropriate cell death, has wide
ranging clinical implications. A number of diseases associated with such deregulation
involve hyperproliferation, inflammation, tissue remodeling and repair. Familiar
indications in this category include cancers, restenosis, neointimal hyperplasia,
angiogenesis, endometriosis, lymphoproliferative disorders, transplantation related
pathologies (graft rejection), polyposis, loss of neural function in the case of tissue
remodeling and the like.
Cancer is associated with abnormal cell proliferation and cell death rates. As
apoptosis is inhibited or delayed in most types of proliferative, neoplastic diseases,
induction of apoptosis is an option for treatment of cancer, especially in cancer types
which show resistance to classic chemotherapy, radiation and immunotherapy
(Apoptosis and Cancer Chemotherapy, Hickman and Dive, eds., Blackwell
Publishing, 1999). Also in autoimmune and transplantation related diseases and
pathologies compounds inducing apoptosis may be used to restore normal cell death
processes and therefore can eradicate the symptoms and might cure the diseases.
Further applications of compounds inducing apoptosis may be in restenosis, i.e.
accumulation of vascular smooth muscle cells in the walls of arteries, and in
persistent infections caused by a failure to eradicate bacteria- and virus-infected
cells. Furthermore, apoptosis can be induced or reestablished in epithelial cells, in
endothelial cells, in muscle cells, and in others which have lost contact with
extracellular matrix.
A compound according to general formula I may be used for the prophylactic
or especially therapeutic treatment of the human or animal body, in particular for
treating a neoplastic disease, autoimmune disease, transplantation related pathology
and/or degenerative disease. Examples of such neoplastic diseases include, but are
not limited to, epithelial neoplasms, squamous cell neoplasms, basal cell neoplasms,
transitional cell papillomas and carcinomas, adenomas and adenocarcinomas,
adnexal and skin appendage neoplasms, mucoepidermoid neoplasms, cystic
neoplasms, mucinous and serous neoplasms, ducal-, lobular and medullary
neoplasms, acinar cell neoplasms, complex epithelial neoplasms, specialized
gonadal neoplasms, paragangliomas and glomus tumours, naevi and melanomas,
soft tissue tumours and sarcomas, fibromatous neoplasms, myxomatous neoplasms,
lipomatous neoplasms, myomatous neoplasms, complex mixed and stromal
neoplasms, fibroepithelial neoplasms, synovial like neoplasms, mesothelial
neoplasms, germ cell neoplasms, trophoblastic neoplasms, mesonephromas, blood
vessel tumours, lymphatic vessel tumours, osseous and chondromatous neoplasms,
giant cell tumours, miscellaneous bone tumours, odontogenic tumours, gliomas,
neuroepitheliomatous neoplasms, meningiomas, nerve sheath tumours, granular cell
tumours and alveolar soft part sarcomas, Hodgkin's and non-Hodgkin's lymphomas,
other lymphoreticular neoplasms, plasma cell tumours, mast cell tumours,
immunoproliferative diseases, leukemias, miscellaneous myeloproliferative disorders,
lymphoproliferative disorders and myelodysplastic syndromes.
The compounds of general formula I or pharmaceutically acceptable
derivatives thereof may be used to treat autoimmune diseases. Examples of such
autoimmune diseases include, but are not limited to, systemic, discoid or subacute
cutaneous lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome,
CREST, progressive systemic sclerosis, mixed connective tissue disease (Sharp
syndrome), Reiter's syndrome, juvenile arthritis, cold agglutinin disease, essential
mixed cryoglobulinemia, rheumatic fever, ankylosing spondylitis, chronic polyarthritis,
myasthenia gravis, multiple sclerosis, chronic inflammatory demyelinating
polyneuropathy, Guillan-Barre syndrome, dermatomyositis/ polymyositis,
autoimmune hemolytic anemia, thrompocytopenic purpura, neutropenia, type I
diabetes mellitus, thyroiditis (including Hashimoto's and Grave's disease), Addison's
disease, polyglandular syndrome, pemphigus (vulgaris, foliaceus, sebaceous and
vegetans), bullous and cicatricial pemphigoid, pemphigoid gestationis, epidermolysis
bullosa acquisita, linear IgA disease, lichen sclerosus et atrophicus, morbus Duhring,
psoriasis vulgaris, guttate, generalized pustular and localized pustular psoriasis,
vitiligo, alopecia areata, primary biliary cirrhosis, autoimmune hepatitis, all forms of
glomerulonephritis, pulmonal hemorrhage (goodpasture syndrome), IgA
nephropathy, pernicious anemia and autoimmune gastritis, inflammatory bowel
diseases (including colitis ulcerosa and morbus Crohn), Behcet's disease, Celic-
Sprue disease, autoimmune uveitis, autoimmune myocarditis, granulomatous
orchitis, aspermatogenesis without orchitis, idiopatic and secondary pulmonary
fibrosis, inflammatory diseases with a possibility of autoimmune pathogensesis, such
as pyoderma gangrensosum, lichen ruber, sarcoidosis (including Lofgren and
cutaneous/subcutaneous type), granuloma anulare, allergic type I and type IV
immunolgical reaction, asthma bronchiale, pollinosis, atopic, contact and airborne
dermatitis, large vessel vasculitis (giant cell and Takayasu's arteritis), medium sized
vessel vasculitis (polyarteritis nodosa, Kawasaki disease), small vessel vasculitis
(Wegener's granulomatosis, Churg Strauss syndrome, microscopic polangiitis,
HenochSchoenlein purpura, essential cryoglobulinemic vasculitis, cutaneous
leukoklastic angiitis), hypersensitivity syndromes, toxic epidermal necrolysis
(Stevens-Johnson syndrome, erythema multiforme), diseases due to drug side
effects, all forms of cutaneous, organ- specific and systemic effects due to type l-vu
(Coombs classification) immunologic forms of reaction, transplantation related
pathologies, such as acute and chronic graft versus host and host versus graft
disease, involving all organs (skin, heart, kidney, bone marrow, eye, liver, spleen,
lung, muscle, central and peripheral nerve system, connective tissue, bone, blood
and lymphatic vessel, genito-urinary system, ear, cartillage, primary and secondary
lymphatic system including bone marrow, lymph node, thymus, gastrointestinal tract,
including oro-pharynx, esophageus, stomach, small intestine, colon, and rectum,
including parts of above mentioned organs down to single cell level and
substructures, e. g. stem cells).
Particularly preferably, the disease according to the invention is a neoplastic
or autoimmune disease. In an especially preferred embodiment the disease is
cancer.
Examples of cancers in terms of the organs and parts of the body affected
include, but are not limited to, the breast, cervix, ovaries, colon, rectum, (including
colon and rectum i.e. colorectal cancer), lung, (including small cell lung cancer, non-
small cell lung cancer, large cell lung cancer and mesothelioma), endocrine system,
bone, adrenal gland, thymus, liver, stomach, intestine, (including gastric cancer),
pancreas, bone marrow, hematological malignancies, (such as lymphoma, leukemia,
myeloma or lymphoid malignancies), bladder, urinary tract, kidneys, skin, thyroid,
brain, head, neck, prostate and testis. Preferably the cancer is selected from the
group consisting of breast cancer, prostate cancer, cervical cancer, ovarian cancer,
gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, brain cancer,
neuroendocrine cancer, lung cancer, kidney cancer, hematological malignancies,
melanoma and sarcomas. Especially preferably the cancer is selected from the
group consisting of breast cancer, cervical cancer, ovarian cancer, gastric cancer,
pancreatic cancer, colon cancer and lung cancer. More especially preferably the
cancer is selected from the group consisting of cervical cancer, gastric cancer,
ovarian cancer, pancreatic cancer, colon cancer and lung cancer.
Samples
The measurement of the level of BUBR1 may be performed in vitro, on a
sample of biological tissue derived from the subject. The sample may be any
biological material separated from the body such as, for example, normal tissue,
tumour tissue, cell lines, plasma, serum, whole blood, cerebrospinal fluid, lymph fluid,
circulating tumour cells, cell lysate, tissue lysate, urine and aspirates. Preferably the
sample is derived from normal tissue, tumour tissue, cell lines, circulating tumour
cells or blood. More preferably the sample is derived from tumour tissue or circulating
tumour cells. In one particularly preferred embodiment the sample is derived from
tumour tissue. For example, the level of BUBR1 may be measured in a fresh, frozen
or formalin fixed/paraffin embedded tumour tissue sample.
The sample is pre-obtained from the subject before the sample is subjected
to the method steps involving measuring the level of the biomarker. The methods for
removal of the sample are well known in the art, and it may for example be removed
from the subject by biopsy, for example by punch biopsy,core biopsy or aspiration
fine needle biopsy, endoscopic biopsy, or surface biopsy. A blood sample may be
collected by venipuncture and further processed according to standard techniques.
Circulating tumour cells may also be obtained from blood based on, for example, size
(e.g. ISET - Isolation by Size of Epithelial Tumour cells) or immunomagnetic cell
enrichment. (e.g. CellSearch , Veridex, Raritan, NJ).
Sample comparison
The subject described herein may be human or animal. Preferably the
subject is human.
The biomarker BUBR1 is measured ex vivo in a sample or samples taken
from the human or animal body, preferably taken from the human body. The sample
or samples are pre-obtained from the human or animal body, preferably pre-obtained
from the human body before the sample is subjected to the method steps involving
measuring the level of the biomarker.
A biomarker is in general a substance that is used as an indicator of a
biological response, preferably as an indicator of the susceptibility to a given
treatment, which in the present application is treatment with a compound of general
formula I or a pharmaceutically acceptable derivative thereof.
In a particularly preferred embodiment, lower BUBR1 levels in the sample
relative to a standard value or set of standard values predicts resistance. As used
herein, a decrease or relatively low or low or lower levels relative to a standard level
or set of standard levels means the amount or concentration of the biomarker in a
sample is detectably less in the sample relative to the standard level or set of
standard levels. This encompasses at least a decrease of, or lower level of, about
1% relative to the standard, preferably at least a decrease of about 5% relative to the
standard. More preferably it is a decrease of, or lower level of, at least about 10%
relative to the standard. More particularly preferably it is a decrease of, or lower level
of, at least about 20% relative to the standard. For example, such a decrease of, or
lower level of, may include, but is not limited to, at least about 1%, about 10%, about
%, about 30%, about 50%, about 70%, about 80%, about 90% or about a 100%
decrease relative to the standard. Thus a decrease also includes the absence of
detectable BUBR1 in the sample.
Preferably, lower BUBR1 levels in a sample or samples
i) relative to a standard value or set of standard values from subjects with
the same tumour histotype; or
ii) taken after treatment initiation and compared to a sample or samples
taken from the same subject before treatment initiation, or
iii) relative to a standard value or set of standard values from normal cells,
tissue or body fluid;
are predictive of resistance.
The measuring of a level of BUBR1 is performed ex-vivo in a sample pre-
obtained from the subject. Further preferably the response which is to be predicted is
resistance.
More preferably, lower BUBR1 levels in a sample or samples
i) relative to a standard value or set of standard values from subjects with
the same tumour histotype; or
ii) taken after treatment initiation and compared to a sample or samples
taken from the same subject before treatment initiation;
are predictive of resistance.
Especially preferably, lower BUBR1 levels in a sample or samples relative to
a standard value or set of standard values from subjects with the same tumour
histotype are predictive of resistance.
In one preferred embodiment, for the case i) where the measurement is
compared in a sample or samples relative to a standard value or set of standard
values from samples from subjects with the same tumour histotype as the sample to
which it is to be compared, the standard value or set of standard values are
established from samples from a population of subjects with that cancer type. The
samples from these standard subjects may for example be derived from tumour
tissue or from circulating tumour cells, as long as the origin of the sample is
consistent between the standard and the sample to be compared.
In another preferred embodiment, for the case ii) where the measurement is
compared in a sample or samples taken after treatment initiation and compared to a
sample or samples taken from the same subject before treatment initiation, it is
measured preferably to predict acquired resistance. The samples are compared to
cells or tissue from the same biological origin. The prediction of acquired resistance
would then indicate that the treatment with the compound should be discontinued.
The biomarker is thus used to monitor whether further treatment with the compound
is likely to give the required response (e.g. reduction of abnormal cells), or whether
the cells have become non-responsive or resistant to such treatment.
In yet another preferred embodiment, for the case iii) where the
measurement is compared in a sample or samples relative to a standard value or set
of standard values from normal cells, tissue or body fluid, the standard value or set of
standard values may be established from a sample of normal (e.g. non-tumourous)
cells, tissue or body fluid . Such data may be gathered from a population of subjects
in order to develop the standard value or set of standard values.
The standard value or set of standard values are established ex-vivo from
pre-obtained samples which may be from cell lines, or preferably biological material
from at least one subject and more preferably from an average of subjects (e.g., n=2
to 1000 or more).
The standard value or set of standard values may then be correlated with the
response data of the same cell lines, or same subjects, to treatment with a
compound of general formula I or a pharmaceutically acceptable derivative thereof.
From this correlation a comparator module, for example in the form of a relative scale
or scoring system, optionally including cut-off or threshold values, can be established
which indicates the levels of biomarker associated with a spectrum of response
levels to the compound of formula I or a pharmaceutically acceptable derivative
thereof. The spectrum of response levels may comprise relative sensitivity to the
therapeutic activity of the compound, (e.g. high sensitivity to low sensitivity), as well
as resistance to the therapeutic activity. In a preferred embodiment this comparator
module comprises a cut-off value or set of values which predicts resistance to
treatment.
For example, if an immunohistochemical method is used to measure the
level of BUBR1 in a sample, standard values may be in the form of a scoring system.
Such a system might take into account the percentage of cells in which staining for
BUBR1 is present. The system may also take into account the relative intensity of
staining in the individual cells. The standard values or set of standard values of the
level of BUBR1 may then be correlated with data indicating the response, especially
resistance, of the subject or tissue or cell line to the therapeutic activity of a
compound of formula I or a pharmaceutically acceptable derivative thereof. Such
data may then form part of a comparator module.
Response is the reaction of the cell lines, or preferably of the subject, or
more preferably of the disease in a subject, to the activity, preferably therapeutic
activity, of a compound of general formula I or a pharmaceutically acceptable
derivative thereof. The spectrum of response levels may comprise relative sensitivity
to the activity, preferably therapeutic activity, of the compound, (e.g. high sensitivity
to low sensitivity), as well as resistance to the activity, preferably therapeutic activity.
The response data may for example be monitored in terms of: objective response
rates, time to disease progression, progression free survival, and overall survival.
The response of a cancerous disease may be evaluated by using criteria
well known to a person in the field of cancer treatment, for example but not restricted
Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines, Source:
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J,
Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R,
Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer.2009 ;45:228-47;
RANO Criteria for High-Grade Gliomas, Source: Wen PY, Macdonald DR, Reardon
DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR,
Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn
KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment
criteria for high-grade gliomas: response assessment in neuro-oncology working
group. J Clin Oncol. 2010;28(11):1963-72;
CA-125 Rustin Criteria for Ovarian Cancer Response,
Source: Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A,
Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J. Re: New
guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J
Natl Cancer Inst. 2004;96(6):487-8;
PSA Working Group 2 Criteria for Prostate Cancer Response,
Source: Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA,
Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E,
Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate
Cancer Clinical Trials Working Group. Design and end points of clinical trials for
patients with progressive prostate cancer and castrate levels of testosterone:
recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol.
2008;26(7):1148-59.
Resistance is associated with there not being an observable and/or
measurable reduction in, or absence of, one or more of the following: reduction in the
number of abnormal cells, preferably cancerous cells or absence of the abnormal
cells, preferably cancerous cells; for cancerous diseases: reduction in tumour size;
inhibition (i.e., slowed to some extent and preferably stopped) of further tumour
growth; reduction in the levels of tumour markers such as PSA and CA-125, inhibition
(i.e., slowed to some extent and preferably stopped) of cancer cell infiltration into
other organs (including the spread of cancer into soft tissue and bone); inhibition (i.e.,
slowed to some extent and preferably stopped) of tumour metastasis; alleviation of
one or more of the symptoms associated with the specific cancer; and reduced
morbidity and mortality.
In a preferred embodiment resistance means there is no observable and/or
measurable reduction in, or absence of, one or more of the following criteria:
reduction in tumour size; inhibition of further tumour growth, inhibition of cancer cell
infiltration into other organs; and inhibition of tumour metastasis.
In a more preferred embodiment resistance refers to one or more of the
following criteria : no reduction in tumour size; no inhibition of further tumour growth,
no inhibition of cancer cell infiltration into other organs; and no inhibition of tumour
metastasis.
Measurement of the aforementioned resistance criteria is according to
clinical guidelines well known to a person in the field of cancer treatment, such as
those listed above for measuring the response of a cancerous disease.
Response may also be established in vitro by assessing cell proliferation
and/or cell death. For example, effects on cell death or proliferation may be assessed
in vitro by one or more of the following well established assays: A) Nuclear staining
with Hoechst 33342 dye providing information about nuclear morphology and DNA
fragmentation which are hallmarks of apoptosis. B) AnnexinV binding assay which
reflects the phosphatidylserine content of the outer lipid bilayer of the plasma
membrane. This event is considered an early hallmark of apoptosis. C) TUNEL assay
(Terminal deoxynucleotidyl transferase mediated dUTP Nick End Labeling assay), a
fluorescence method for evaluating cells undergoing apoptosis or necrosis by
measuring DNA fragmentation by labeling the terminal end of nucleic acids. D) MTS
proliferation assay measuring the metabolic activity of cells. Viable cells are
metabolically active whereas cells with a compromised respiratory chain show a
reduced activity in this test. E) Crystal violet staining assay, where effects on cell
number are monitored through direct staining of cellular components. F) Proliferation
assay monitoring DNA synthesis through incorporation of bromodeoxyuridine (BrdU).
Inhibitory effects on growth/proliferation can be directly determined. G) YO-PRO
assay which involves a membrane impermeable, fluorescent, monomeric cyanine,
nucleic acid stain, which permits analysis of dying (e.g. apoptotic) cells without
interfering with cell viability. Overall effects on cell number can also be analysed after
cell permeabilisation. H) Propidium iodide staining for cell cycle distribution which
shows alterations in distribution among the different phases of the cell cycle. Cell
cycle arresting points can be determined. I) Anchorage-independent growth assays,
such as colony outgrowth assays which assess the ability of single cell suspensions
to grow into colonies in soft agar.
In a preferred embodiment relating to determination of resistance in vitro,
resistance means there is no decrease in the proliferation rate of abnormal cells
and/or reduction in the number of abnormal cells. More preferably resistance means
there is no decrease in the proliferation rate of cancerous cells and/or no reduction in
the number of cancerous cells. The reduction in the number of abnormal, preferably
cancerous, cells may occur through a variety of programmed and non-programmed
cell death mechanisms. Apoptosis, caspase-independent programmed cell death and
autophagic cell death are examples of programmed cell death. However the cell
death criteria involved in embodiments of the invention is not to be taken as limited to
any one cell death mechanism.
BUBR1
As described above, the term BUBR1 is used herein to encompass all the
previously mentioned synonyms and refers to this entity on both the nucleic acid and
protein levels as appropriate. Nucleic acid levels refer to for example mRNA, cDNA
or DNA and the term protein includes the translated polypeptide or protein sequence
and post-translationally modified forms thereof.
A preferred example of the protein sequence of BUBR1 (human BUBR1) is
listed in SEQ. ID No. 1, Figure 18. However the term BUBR1 also encompasses
homologues, mutant forms, allelic variants, isotypes, splice variants and equivalents
of this sequence. Preferably also it encompasses human homologues, mutant forms,
allelic variants, isotypes, splice variants and equivalents of this sequence. More
preferably it encompasses sequences having at least about 75% identity, especially
preferably at least about 85% identity, particularly preferably at least about 95%
identity, and more particularly preferably about 99% identity, to said sequence.
In an especially preferred embodiment, BUBR1 is the entity on the nucleic
acid or protein levels, which is represented on the protein level by SEQ ID NO. 1 or
sequences having at least 95% identity with this sequence, preferably at least 99%
identity. In a particularly preferred embodiment, BUBR1 is represented by SEQ. ID.
No.1.
A preferred example of the nucleic acid sequence of BUBR1 (Human
BUBR1) is accessible via NCBI Reference Sequence NM_001211, and is listed in
SEQ. ID. No. 2 (NM_001211.5), Figure 19. The term BUBR1 also encompasses
modifications, more degenerate variants of said sequence, complements of said
sequence, and oligonucleotides that hybridise to one of said sequences. Such
modifications include, but are not limited to, mutations, insertions, deletions, and
substitutions of one or more nucleotides. More preferably it encompasses sequences
having at least about 75% identity to said sequence, especially preferably at least
about 85% identity, particularly preferably at least about 95% identity and more
particularly preferably about 99% identity.
In yet another preferred embodiment, BUBR1 is the entity on the nucleic
acid or protein levels, which is represented on the nucleic acid level by SEQ ID NO. 2
or sequences having at least 95% identity with this sequence, preferably at least 99%
identity. In a particularly preferred embodiment, BUBR1 is represented by SEQ. ID.
No. 2.
Level of BUBR1
The level of BUBR1 may be assayed in the sample by technical means well
known to a skilled person. It may be assayed at the transcriptional or translational
level.
In one preferred embodiment the level of BUBR1 nucleic acid, preferably
BUBR1 mRNA, in a sample is measured. Examples of methods of gene expression
analysis known in the art which are suitable to measure the level of BUBR1 at the
nucleic acid level include, but are not limited to, i) using a labelled probe that is
capable of hybridising to mRNA; ii) using PCR involving one or more primers based
on the BUBR1 gene sequence, for example using quantitative PCR methods using
labelled probes, e.g. fluorogenic probes, such as quantitative real-time PCR; iii)
micro-arrays; IV) northern blotting V) serial analysis of gene expression (SAGE),
READS (restriction enzyme amplification of digested cDNAs), differential display and
measuring microRNA.
In a preferred embodiment the level of BUBR1 at the protein level is
measured. Examples of methods of protein expression analysis known in the art
which are suitable to measure the level of BUBR1 at the protein level include, but are
not limited to, i) immunohistochemistry (IHC) analysis, ii) western blotting iii)
immunoprecipitation iv) enzyme linked immunosorbant assay (ELISA) v)
radioimmunoassay vi) Fluorescence activated cell sorting (FACS) vii) mass
spectrometry, including matrix assisted laser desorption/ionization (MALDI, e.g.
MALDI-TOF) and surface enhanced laser desorption/ionization (SELDI, e.g. SELDI-
TOF).
The antibodies involved in some of the above methods may be monoclonal
or polyclonal antibodies, antibody fragments, and/or various types of synthetic
antibodies, including chimeric antibodies. The antibody may be labelled to enable it
to be detected or capable of detection following reaction with one or more further
species, for example using a secondary antibody that is labelled or capable of
producing a detectable result. Antibodies specific to BUBR1 are available
commercially from BD Transduction Laboratories and Cell Signaling Technology,
Inc., or can be prepared via conventional antibody generation methods well known to
a skilled person.
Preferred methods of protein analysis are ELISA, mass spectrometry
techniques, immunohistochemistry and western blotting, more preferably western
blotting and immunohistochemistry. In western blotting, also known as
immunoblotting, labelled antibodies may be used to assess levels of protein, where
the intensity of the signal from the detectable label corresponds to the amount of
protein, and can be quantified for example by densitometry.
Immunohistochemistry again uses labelled antibodies to detect the presence
and relative amount of the biomarker. It can be used to assess the percentage of
cells for which the biomarker is present. It can also be used to assess the localisation
or relative amount of the biomarker in individual cells; the latter is seen as a function
of the intensity of staining.
ELISA stands for enzyme linked immunosorbant assay, since it uses an
enzyme linked to an antibody or antigen for the detection of a specific protein. ELISA
is typically performed as follows (although other variations in methodology exist): a
solid substrate such as a 96 well plate is coated with a primary antibody, which
recognises the biomarker. The bound biomarker is then recognised by a secondary
antibody specific for the biomarker. This may be directly joined to an enzyme or a
third anti-immunoglobulin antibody may be used which is joined to an enzyme. A
substrate is added and the enzyme catalyses a reaction, yielding a specific colour.
By measuring the optical density of this colour, the presence and amount of the
biomarker can be determined.
Uses of biomarker
In one preferred embodiment, the biomarker is used to predict inherent
resistance of the disease in a subject to the compound of general formula I or a
pharmaceutically acceptable derivative thereof as defined above.
In another preferred embodiment, the biomarker is used to predict acquired
resistance of the disease in a subject to the compound of general formula I or a
pharmaceutically acceptable derivative thereof as defined above.
The biomarker may be used to select subjects suffering or predisposed to
suffering from a disease, preferably cancer, for treatment with a compound of general
formula I or a pharmaceutically acceptable derivative thereof as defined above. The
levels of such a biomarker may be used to identify patients likely to respond or to not
respond or to continue to respond or to not continue to respond to treatment with
such agents. Stratification of patients may be made in order to avoid unnecessary
treatment regimes. In particular the biomarker may be used to identify subjects from
whom a sample or samples do not display a lower level of BUBR1, relative to a
standard level or set of standard levels, whereupon such subjects may then be
selected for treatment with the compound of formula I or a pharmaceutically
acceptable derivative thereof as defined above.
The biomarker may also be used to assist in the determination of treatment
regimes, regarding amounts and schedules of dosing. Additionally, the biomarker
may be used to assist in the selection of a combination of drugs to be given to a
subject, including a compound or compounds of general formula I or a
pharmaceutically acceptable derivative thereof, and another chemotherapeutic
(cytotoxic) agent or agents. Furthermore, the biomarker may be used to assist in the
determination of therapy strategies in a subject including whether a compound of
general formula I or a pharmaceutically acceptable derivative thereof is to be
administered in combination with targeted therapy, endocrine therapy, radiotherapy,
immunotherapy or surgical intervention, or a combination of these.
BUBR1 may also be used in combination with other biomarkers to predict
the response to a compound of general formula I or a pharmaceutically acceptable
derivative thereof and to determine treatment regimes. It may furthermore be used in
combination with chemo-sensitivity testing to predict resistance and to determine
treatment regimes. Chemo-sensitivity testing involves directly applying a compound
of general formula I to cells taken from the subject, for example from a subject with
haematological malignancies or accessible solid tumours, for example breast and
head and neck cancers or melanomas, to determine the response of the cells to the
compound.
Method of treatment
Also described is a method of treatment and BUBR1 for use in a method of
treatment, wherein the level of BUBR1 is first established relative to a standard level
or set of standard levels or pre-treatment initiation levels and then a compound of
general formula I or a pharmaceutically acceptable derivative thereof as defined
above, is administered if the level of BUBR1 in said sample is not lower than a
standard value or set of standard values or has not decreased relative to pre-
treatment initiation levels respectively. The compound of formula I or a
pharmaceutically acceptable derivative thereof may be administered in a
pharmaceutical composition, as is well known to a person skilled in the art. Suitable
compositions and dosages are for example disclosed in A1 pages
-39, which are specifically incorporated by reference herein. Compositions for
enteral administration, such as nasal, buccal, rectal or, especially, oral
administration, and for parenteral administration, such as intravenous, intramuscular
or subcutaneous administration, to warm-blooded animals, especially humans, are
especially preferred. More particularly, compositions for intravenous administration
are preferred.
The compositions comprise the active ingredient and a pharmaceutically
acceptable carrier. An example of a composition includes, but is not limited to, the
following: 5000 soft gelatin capsules, each comprising as active ingredient 0.05 g of
one of the compounds of general formula (I), are prepared as follows: 250 g
pulverized active ingredient is suspended in 2 liter Lauroglykol (propylene glycol
laurate, Gattefossé S.A., Saint Priest, France) and ground in a wet pulverizer to
produce a particle size of about 1 to 3 µm. 0.419 g portions of the mixture are then
introduced into soft gelatin capsules using a capsule-filling machine.
Also described is a method of treating a neoplastic or autoimmune disease,
preferably cancer, by first increasing the level of BUBR1 in a subject that has a
sample with a lower level of BUBR1 compared to a standard level or set of standard
levels, or pre-treatment initiation levels, then treating the subject with a compound of
general formula I or a pharmaceutically acceptable derivative as defined above. The
level of BUBR1 may be increased by direct or indirect chemical or genetic means.
Examples of such methods are treatment with a drug that results in increased
BUBR1 expression and targeted delivery of viral, plasmid or peptide constructs, or
antibody or siRNA or antisense to upregulate the level of BUBR1. For example viral
or plasmid constructs may be used to increase the expression of BUBR1 in the cell.
The subject may then be treated with a compound of general formula I or a
pharmaceutically acceptable derivative thereof.
A compound of general formula I or a pharmaceutically acceptable derivative
thereof can be administered alone or in combination with one or more other
therapeutic agents. Possible combination therapy may take the form of fixed
combinations, or the administration of a compound described herein and one or more
other therapeutic agents which are staggered or given independently of one another,
or the combined administration of fixed combinations and one or more other
therapeutic agents.
A compound of general formula I or a pharmaceutically acceptable
derivative thereof can, besides or in addition, be administered especially for tumour
therapy in combination with chemotherapy (cytotoxic therapy), targeted therapy,
endocrine therapy, radiotherapy, immunotherapy, surgical intervention, or a
combination of these. Long-term therapy is equally possible as is adjuvant therapy in
the context of other treatment strategies, as described above. Other possible
treatments are therapy to maintain the patient's status after tumour regression, or
even chemo-preventive therapy, for example in patients at risk.
Kit and device
Also described is a kit, and in another aspect to a device, for predicting the
response, preferably of a disease in a subject, to a compound of general formula I or
a pharmaceutically acceptable derivative thereof as defined above, comprising
reagents necessary for measuring the level of BUBR1 in a sample. Preferably, the
reagents comprise a capture reagent comprising a detector for BUBR1 and a
detector reagent.
The kit and device may also preferably comprise a comparator module
which comprises a standard value or set of standard values to which the level of
BUBR1 in the sample is compared. In a preferred embodiment, the comparator
module is included in instructions for use of the kit. In another preferred embodiment
the comparator module is in the form of a display device, for example a strip of colour
or numerically coded material which is designed to be placed next to the readout of
the sample measurement to indicate resistance levels. The standard value or set of
standard values may be determined as described above.
The reagents are preferably antibodies or antibody fragments which
selectively bind to BUBR1. These may for example be in the form of one specific
primary antibody which binds to BUBR1 and a secondary antibody which binds to the
primary antibody, and which is itself labelled for detection. The primary antibody may
also be labelled for direct detection. The kits or devices may optionally also contain a
wash solution(s) that selectively allows retention of the bound biomarker to the
capture reagent as compared with other biomarkers after washing. Such kits can
then be used in ELISA, western blotting, flow cytometry, immunohistochemical or
other immunochemical methods to detect the level of the biomarker.
The reagents may also in another preferred embodiment be those that are
capable of measuring the level of BUBR1 nucleic acids in a sample. Suitable
samples are tissue or tumour tissue samples, sections of fixed and paraffin-
embedded or frozen tissue or tumour tissue specimens, circulating tumour cells and
blood and body liquid-derived samples. Preferably, the reagents comprise a labelled
probe or primers for hybridisation to BUBR1 nucleic acid in the sample. Suitable
detection systems, either based on PCR amplification techniques or detection of
labelled probes, allow quantification of BUBR1 nucleic acid in the sample. This can
be done i) in-situ on the specimen itself, preferably in sections from paraffin-
embedded or frozen specimens, ii) in extracts from tumour, tissue or blood-derived
specimens, where suitable reagents selectively enrich for nucleic acids. The kits or
devices enable the measurement and quantification of i) the amount of hybridised
labelled probes to the specimens in-situ or ii) the amount of primer-based
amplification products by methods based on specific physico-chemical properties of
the probes itself or the reporters attached to the primers.
Furthermore the device may comprise imaging devices or measurement
devices (for example, but not restricted to, measurement of fluorescence) which
further process the measured signals and transfer them into a scale in a comparator
module.
More preferably the kit comprises a compound of general formula I, or a
pharmaceutically acceptable derivative thereof as defined above. This compound
may then be administered to the subject, in accordance with the level of the
biomarker in the sample from the subject, as measured by the reagents comprised in
the kit. Therefore the kit described herein may be used in the method of treatment
according to the invention, as defined above. In an especially preferred embodiment
the kit comprises a compound of the following formula or a pharmaceutically
acceptable salt thereof.
In a particularly preferred embodiment of the kit the salt is a dihydrochloride
salt. In another aspect the invention relates to the use of such a kit as described
above.
In the present specification the words “comprise” or “comprises” or
“comprising” are to be understood as to imply the inclusion of a stated item or group
of items, but not the exclusion of any other item or group of items.
Experimental methodology
Immunofluorescent staining of cultured cells
A549 human non-small cell lung cancer (NSCLC, ATCC reference number
CCL-185) cells, HeLa cervical cancer cells (ATCC reference number CCL-2) and
SKBR3 breast carcinoma cells (ATCC reference number HTB-30) were seeded at
densities of 50% on round microscope coverslips and cultured for 24 hours in RPMI-
1640 containing 10 % FCS (also referred to as FBS) at 37°C, 5% CO . Compounds
to be tested were dissolved in DMSO. The cell culture medium was replaced with
medium containing the diluted compound(s) (paclitaxel, vinblastine, colchicine and
nocodazole were purchased from Sigma-Aldrich) or vehicle. After treatment,
coverslips were washed and cells were fixed in methanol/acetone (1:1) for 5 minutes
at room temperature and subsequently incubated in blocking buffer (0.5% BSA and
0.1% TX-100 in PBS) for 30 minutes at room temperature. Specimens were then
incubated with anti-alpha-tubulin antibody (Sigma, 1:2000) for 1 hour at room
temperature in blocking buffer. After several washing steps cells were incubated with
AlexaFluor-488 goat-anti-mouse IgG (Molecular Probes, 1:3000) for 1 hour at room
temperature followed by several washing steps with blocking buffer. Specimens were
then mounted with ProLong Gold antifade (Molecular Probes), sealed with nail polish
and examined with a Leica immunofluorescence microscope. Images were captured
with a cooled CCD-camera and processed by ImageJ software.
siRNA transfection
In order to show BUBR1 is a biomarker of resistance, siRNA experiments
were performed. For siRNA experiments to assess effects on tumour cell phenotype
and numbers (Figure 8), HeLa (ATCC reference CCL-2) cervical cancer cells were
cultured at 37°C and 5 % CO in DMEM with 10 % FCS (Invitrogen). 1000 HeLa cells
per well were seeded into black 384 well multititer plates (BD Falcon). Cells were
reversely transfected with 20 nM non-targeting control siRNA (ON-Target-plus non-
targeting pool D001810, Dharmacon) or a mixture of four BUBR1 siRNAs (ON-
Target-plus Smartpool L-004101, Dharmacon, see sequence information below)
using Dharmafect1 (Dharmacon, Thermo) transfection reagent. 48 hours after cell
seeding and siRNA transfection, one replicate pair of siRNA clones was treated with
BAL27862 (50 nM, 0.1 % DMSO) and another replicate pair with control solution (0.1
% DMSO) for 24 hours. The experiment was terminated by methanol-based fixation
(-20°C, 5 min) and subsequent immunostaining (1 hour, room temperature) using
alpha-tubulin (FITC labelled, 1:500, F2168, Sigma) and actin (TRITC-phalloidin,
1:3000, P1951, Sigma) antibodies as well as Hoe33342 DNA stain (1:8000, Sigma).
Based on the immunostaining, the morphology of treated cells was analysed using a
multiparametric approach (BD Pathway 855 fluorescence microscope; 20x objective)
with appropriate software. The number of cells per well was also calculated based on
Hoe33342 staining of nuclei. This enabled calculation of the fraction of cells
displaying an untreated (normal) phenotype (in %).
For siRNA experiments to assess effects on BUBR1 expression levels by
immunoblotting and effects on tumour cell proliferation and viability using the YO-
PRO assay (Figures 7, 9,10 and 11), and Crystal Violet Assay (Figures 12 and 13),
cells were seeded in 6 well plates at an appropriate density: HeLa (cervical cancer
cells; ATCC reference CCL-2) 2.5E+04 (for YO-PRO) or 4.0E+04 (for Crystal Violet)
cells per well, H460 (NSCLC cells; ATCC reference HTB-177) 5.0E+04 cells per well,
MCF-7 (breast carcinoma cells; ATCC reference HTB-22) 2.4E+05 cells per well,
Panc1 (pancreatic cancer cells, ATCC reference CRL-1469) and HCT116 (colon
cancer cells, ATCC reference CCl-247) 8E+04 cells per well, and were cultured at
37°C and 5 % CO in RPMI-1640 or DMEM containing 10% FCS (complete medium).
Cells were transfected the following day with a mixture of four BUBR1 siRNAs (ON-
Target-plus Smartpool L-004101, Dharmacon, see sequence information below), the
four individual BUBR1 siRNAs (ON-Target-plus Set of four upgrade LU-004101) or
non-targeting control siRNAs (ON-Target-plus non-targeting pool D001810,
Dharmacon), using Hiperfect (Qiagen) for H460, Panc1 and HCT116 or
Lipofectamine2000 (Invitrogen) for HeLa and MCF-7 according to manufacturer´s
instructions. The final concentration of siRNA was 10 nM (H460) or 20-30 nM (HeLa)
or 20 nM (MCF-7, Panc1, HCT116). Cells were maintained at 37°C and 5 % CO for
24 hours before compound treatment for 48 hours, followed by YO-PRO analysis,
Crystal Violet Assay or extraction for immunoblot assay. ON-Target-plus siRNAs are
dual-strand siRNAs, chemically modified to improve specificity for the desired target.
The sequences of the four BUBR1 siRNAs used were:
ON-TARGETplus BUBR1 siRNA #1 SEQ ID. No. 3
' GAUGGUGAAUUGUGGAAUA
ON-TARGETplus BUBR1 siRNA #2 SEQ ID. No. 4
5' GAAACGGGCAUUUGAAUAU
ON-TARGETplus BUBR1 siRNA #3 SEQ ID. No. 5
' GCAAUGAGCCUUUGGAUAU
ON-TARGETplus BUBR1 siRNA #4 SEQ ID. No. 6
' CAAUACAGCUUCACUGAUA
YO-PRO Assay of siRNA-treated Cells
BAL27862, dissolved in DMSO, was diluted into complete medium before
addition to the cells at the indicated concentrations (final concentration DMSO 0.5
%). Cells were incubated for 48 hours followed by YO-PRO analysis.
YO-PRO -1 iodide is a membrane impermeable, fluorescent, monomeric
cyanine, nucleic acid stain, which permits analysis of dying (e.g. apoptotic) cells
without interfering with cell viability.
12.5 µl YO-PRO -1 iodide (491/509)(Invitrogen/Molecular Probes, # Y-3603;
1mM in DMSO) were added to 1 ml 5-times concentrated YO-PRO buffer (100 mM
Na-citrate, pH 4.0; 134 mM NaCl) to produce the YO-PRO Mix. For the determination
of cytotoxicity/apoptosis, 500 µl of YO-PRO Mix were added per well in 6 well plates
(dilution 1:5), and incubated for 10 min at room temperature in the dark. The uptake
of YO-PRO dye into cells was assessed by using a SpectraMax M2 plate reader
(Molecular Devices) using 485 nm excitation and 538 nm emission at a cutoff of 530
nm. For the determination of overall effects on cell growth/total cell number, 500 µl of
Lysis buffer (30mM EDTA; 30mM EGTA; 0.6% NP-40; in 0.33 times YO-PRO buffer)
were added per well and incubated for 30 min at room temperature in the dark.
Fluorescent read-out was performed in a SpectraMax M2 plate reader (Molecular
Devices) using 485 nm excitation and 538 nm emission at a cut off of 530 nm. The %
of dead cells was calculated as a percentage of the total remaining cell number.
Crystal Violet Assay of siRNA-treated Cells
Cells were incubated for 48 hours with DMSO or BAL27862 diluted in
complete medium (final concentration DMSO 0.5 %). After medium was removed,
cells were fixed and stained by adding 1 ml Crystal Violet Staining (0.2 % Crystal
Violet in 50 % Methanol) per well. Plates were incubated for 1 hour at room
temperature. Subsequently the stain was decanted and plates were washed 4 times
with double-distilled water. Plates were air-dried for several hours. Stain was
dissolved by adding 2 ml buffer (0.1 M Tris pH 7.5, 0.2 % SDS, 20 % Ethanol) per
well and shaking the plates. Absorbance at 590 nm was measured using a
SpectraMax M2 plate reader (Molecular Devices). In order to subtract starting cell
numbers, a control plate was fixed and stained on the same day the compound was
added. Final results were calculated by subtracting the starting cell absorbance from
that of control (DMSO) or compound treated cells. Values lower than zero indicate
cell death.
Colony Outgrowth Assay:
Single cell suspensions of patient-derived tumour xenografts (maintained in
nude mice) were prepared. For colony outgrowth assays, cells were plated in soft
agar in 24-well plates according to the assay introduced by Hamburger & Salmon
(Primary bioassay of human tumour stem cells, Science, 1977,197:461-463).
2.0E+04 - 6.0E+04 cells in 0.2 mL medium containing 0.4 % agar were plated out on
a bottom layer of 0.75 % agar. Test compounds were applied in 0.2 mL culture
medium. Every 24-well plate contained untreated controls and samples in triplicates.
Cultures were incubated at 37°C and 7.5 % CO for 5 - 28 days. 24 hours prior to
analysis, vital colonies were stained with a solution of metabolizable tetrazolium salt
(Alley MC et al, Life Sci. 1982, 31:3071-3078) and were counted with an automatic
image analysis system (Omnicon 3600, Biosys GmbH).
Relative drug effects were expressed by the ratio of the mean number of
colonies in the treated wells and the control wells. IC -values were determined by
plotting compound concentrations versus relative colony counts.
Quantitative Real-time PCR
HeLa cervical cancer and H460 NSCLC (ATCC Reference number HTB-177) cells
were grown in 10 cm-dishes until they reached 80 % confluency, followed by
trypsinisation, pelleting and resuspension in 1 ml Trizol reagent (Invitrogen). Total
RNA was isolated according to manufacturer’s instructions. Real-time PCR was
performed using the TaqMan RNA-to-Ct 1-step kit (Applied Biosystems, reference
number 4392938) and gene expression assays (Applied Biosystems) with 100 ng
RNA per reaction using the ABI Prism 7000 Sequence Detection System. The
following gene expression assays were used: Assay ID Hs01084828_m1 for
quantification of BUBR1 or Assay ID HS99999901_s1 for quantification of 18S-RNA.
All samples were analysed in triplicate. Data analysis was performed using SDS
software (Applied Biosystems). BUBR1 expression levels were normalised to 18S-
RNA.
Generation and Crystal Violet Assay of BAL27862-Resistant Cell Lines
BAL27862-resistant sublines of human non-small cell lung cancer (H460
ATCC reference HTB-177; A549 ATCC reference CCL-185), ovarian cancer (SKOV3
ATCC reference HTB-77) lines were generated by long-term selection in complete
cell culture medium (RPMI-1640 containing 10% FCS; Sigma-Aldrich) by stepwise
increasing concentrations of BAL27862. Dependent on the cell line, the selection
process was carried out for 8-12 months in order to achieve resistance factors (ratio
of IC of resistant cell line and appropriate wild-type cell line) between 3 and 11.6.
The resistant sublines were expanded at the highest tolerated BAL27862
concentration and subsequently frozen and stored in liquid nitrogen.
Cells were seeded in 96 well plates at the following densities: A549: 2000,
H460: 1000, SKOV3: 2000 and, after 24 hours incubation, were incubated for 72
hours with DMSO, BAL27862, colchicine, nocodazole, paclitaxel or vinblastine
diluted in complete medium (final concentration DMSO max. 0.5 %). After medium
was removed, cells were fixed and stained by adding 50 µl Crystal Violet Staining
(0.2 % Crystal Violet in 50 % Methanol) per well. Plates were incubated for 1 hour at
room temperature. Subsequently the stain was decanted and plates were washed 4
times with double-distilled water. Plates were air-dried for several hours. Stain was
dissolved by adding 100 µl buffer (0.1 M Tris pH 7.5, 0.2 % SDS, 20 % Ethanol) per
well and shaking the plates. Absorbance at 590 nm was measured using a
SpectraMax M2e plate reader (Molecular Devices). Anti-proliferative IC values
were calculated from concentration response curves using GraphPad Prism
software. Resistance factors were calculated as a ratio of BAL27862 IC in the
resistant line variant versus the IC in the parental line.
Protein Extraction
Tumour cell extraction: Cells were washed with ice-cold PBS containing
1 mM phenylmethylsulfonyl fluoride (PMSF) and with ice-cold buffer containing
50 mM HEPES (pH 7.5), 150 mM NaCl, 25 mM β-glycerophosphate, 25 mM NaF,
mM EGTA, 1 mM EDTA, 15 mM pyrophosphate, 2 mM sodium orthovanadate,
mM sodium molybdate, leupeptin (10 µg/mL), aprotinin (10 µg/mL) and 1 mM
phenylmethylsulphonyl fluoride (PMSF). Cells were extracted in the same buffer
containing 1% NP-40. After homogenisation, lysates were clarified by centrifugation
and frozen at -80°C.
Immunoblotting/Western Blotting
Immunoblotting was performed using 20 μg of total protein per lane. Total
protein concentration was determined with the BCA Protein Assay (Pierce). Protein
was separated on a 7.5 % SDS-gel and transferred to a PVDF membrane using
Semidry Blotting (90 min, 50 mA/gel). The primary antibodies used for
immunoblotting were as follows:
BUBR1 Ab. No 1: BUBR1 (available from Cell Signaling Technology, Inc,
reference number 4116) origin: rabbit, polyclonal, dilution 1:1000, buffer conditions:
% milk in PBS/0.1% Tween
BUBR1 Ab. No 2: BUBR1 (available from BD Transduction Laboratories,
reference number 612502) origin: mouse, monoclonal, dilution 1:5000, buffer
conditions: 3% BSA in PBS/0.1% Tween
Alpha-tubulin: (available from Sigma, reference number T5168) origin:
mouse, monoclonal, dilution 1:10000, buffer conditions: 5% milk or 3% BSA in
PBS/0.1% Tween
Actin: (available from Chemicon, reference number MAB1501) origin:
mouse, monoclonal, dilution 1:5000, buffer conditions: 5% milk or 3% BSA in
PBS/0.1% Tween
The secondary antibodies used for immunoblotting were peroxidase-
conjugated goat anti-rabbit or goat anti-mouse (available from Jackson
ImmunoResearch Laboratories INC: reference number 111144 JIR and 115-
035-146 JIR), dilution 1:5000, buffer conditions: 0.5% milk in PBS/0.1% Tween.
Labelled bands were revealed using a Raytest Stella 3200 High Performance
Imaging System.
Immunohistochemistry
Fixation of patient-derived tumour xenografts (maintained in nude mice) was
performed in 10 % neutral-buffered formalin containing 4 % formaldehyde for 20 – 28
hours at room temperature. Fixed specimens were kept in a solution of 70 % ethanol
for a maximum of one week prior to dehydration and paraffin embedding according to
a standard procedure, using the conditions listed below:
Sequential Treatment time (hours)
70% EtOH 1
80% EtOH 2
99% EtOH 1
100% Isopropanol 0.5
100% Isopropanol 1
Xylol 0.5
Xylol 1
Xylol 1
Paraffin 1
Paraffin 2
Paraffin 2
Paraffin sections of approximately 2 µm were cut and processed by using
the automated immunostainer Benchmark XT® (Roche) running the standard
processing steps. The visualisation of the specific antibody staining was done with
DAB (3,3-diaminobenzidine) as chromogenic substrate at a concentration of 5 mg/ml.
The following primary antibody and processing conditions were used for staining:
Antibody Specification Processing
Anti-BubR1, BD Transduction Lab, # Cell conditioning 1 buffer from Roche for
612503, mouse Mab 30 minutes, antibody incubation at 37°C for
32 minutes at a dilution of 1:200
Detailed examples
Example 1: A Distinct Mitotic Phenotype Induced by compounds of general
formula I
Treatment with compound A (BAL27862) or with compound B or compound
C, induced a highly reproducible and distinct microtubule phenotype in all tumour cell
lines tested (shown for compound A in A549, HeLa and SKBR3 cells in Figure 1, and
for compound B and compound C in A549 cells in Figure 2). In dividing cells an
apparent fragmentation of the mitotic spindle occurred, resulting in the formation of
dot-like structures (Figure 1). This phenotype was shown to be distinct from that
observed with conventional microtubule targeting agents, such as the microtubule
stabiliser paclitaxel and the microtubule destabilisers vinblastine and colchicine
(Figure 3) and nocodazole (Figure 4).
Example 2: BAL27862 Overcomes Microtubule Phenotype Induced by
Conventional Microtubule-targeting Drugs in a Dominant Fashion
In order to show the uniqueness of its activity on microtubules, BAL27862
was tested in combination with vinblastine, colchicine and paclitaxel (Figure 5) and
nocodazole (Figure 6) using A549 cells. Treatment with vinblastine, colchicine,
paclitaxel or nocodazole alone induced the mitotic microtubule phenotypes
characteristic of these agents. However, combination treatment with BAL27862 for
the last 4 hours resulted in disruption of the microtubule structures; creating a
phenotype consistent with treatment of BAL27862 alone, despite the continued
presence of vinblastine, colchicine, paclitaxel or nocodazole. In contrast, treating first
with BAL27862 and subsequently for 4 hours in combination with vinblastine,
colchicine, paclitaxel or nocodazole had no impact on the observed microtubule
phenotype that was consistent with treatment with BAL27862.
These data demonstrate that compounds of formula I affect microtubule
biology consistently, but in a different manner than conventional microtubule
targeting agents.
Detailed Examples according to the invention
Example 3: siRNA-mediated Down Regulation of BUBR1 Expression
Suppresses the Antiproliferative Effect and Tumour Cell Death Induced by BAL27862
treatment
Through immunoblot analysis (using both BUBR1 Ab. No. 1 and 2) down
regulation of BUBR1 expression using a pool of four BUBR1 siRNAs was shown to
be very efficient in both HeLa cervical tumour and H460 NSCLC cell lines (Figure 7).
Strikingly, analysis of the effects of pooled BUBR1 siRNA treatment on HeLa
cell number and the fraction of HeLa cells with a normal phenotype in the presence
of BAL27862 indicated that BUBR1 was required for optimal effects (Figure 8).
Further analysis of the effects of reduced BUBR1 expression on HeLa cell
proliferation and viability using the YO-PRO assay, indicated that, although loss of
BUBR1 expression itself caused a slight reduction in proliferation rate, the
antiproliferative effect of BAL27862 was dramatically reduced (Figure 9, upper
panel). Moreover, there was no increase in tumour cell death observed, as compared
to a number of BAL27862-treated controls (Figure 9, lower panel).
This effect was shown to be not cell-line or tumour-type-specific, as the
same observation was made after treatment of H460 (Figure 10) and MCF7 breast
cancer cells (Figure 11). Moreover, using an alternative method to analyse cellular
proliferation (Crystal Violet assay), the same effects were again observed in HeLa, as
well as in pancreatic (Panc1) and colon cancer (HCT116) cells (Figure 12).
In order to control the specificity of the BUBR1 siRNA pool used for the
experiments presented in Figs. 7 – 12, the individual siRNAs contained within the
pool were also evaluated. Treatment with all individual siRNAs decreased the effect
of BAL27862 on cellular proliferation (as assessed by Crystal Violet assay)(Figure
13A). Importantly, the degree of reduction correlated with the efficiency of BUBR1
protein down regulation caused by each individual siRNA (compare Figure 13A with
13B).
Example 4: Down Regulation of BUBR1 Expression is Observed in Tumour
Lines Selected for BAL27862 Resistance
In vitro selection for resistance to BAL27862 resulted in the generation of 3
relatively resistant tumour cell lines, with the following resistance factors versus
parental lines (based on IC determinations using the Crystal Violet assay): A549
(3.0 fold); SKOV3 resistant 1 (7.6 fold); SKOV3 resistant 2 (11.6 fold); H460 (5.3
fold)(Table 1).
Table 1:
Resistance factors (ratio of IC BAL27862-resistant cell line
Treatment variant and IC parental cell line)
compound SKOV3 SKOV3
A549 H460
resistant 1 resistant 2
BAL27862 3.0 5.3 7.6 11.6
Colchicine 0.9 1.6 2.0 2.8
Nocodazole 1.6 1.3 3.6 3.9
Vinblastine 2.3 4.6 15.7 17.8
Paclitaxel 0.06 0.3 0.4 0.5
In general these BAL27862-resistant cells exhibited a different level of
response to other microtubule destabilising agents, such as colchicine, nocodazole
and vinblastine, as compared to BAL27862; and indeed increased sensitivity to the
microtubule stabiliser paclitaxel was observed in all lines (Table 1).
Extraction and immunoblot analysis of these lines (with BUBR1 Ab. No. 2,
mouse monoclonal) indicated reduced expression of the BUBR1 protein as
compared to the parental line (Figure 14). This was maintained throughout resistance
development in the SKOV3 cells (Figure 15). These data show the association of the
reduction in BUBR1 expression levels with acquired resistance to BAL27862.
Example 5: Association of low BUBR1 expression levels with patient-derived
tumour cells resistant to BAL27862 treatment.
Based on colony outgrowth assays, using tumour cells derived from patient-
derived tumours maintained as xenografts in mice, BAL27862-sensitive or relatively
resistant tumour cells were identified from gastric and lung cancer (see Table 2).
Concentrations at which 70% growth inhibition was observed versus controls (IC )
are shown in Table 2. In this table, BAL27862-sensitive tumour cells have IC values
in the low nanomolar range, while BAL27862-resistant tumour cells are defined by
IC values >600 nanomolar. Paclitaxel and vinblastine data, using the same ex vivo
assay, was also available for all tumour models. All were resistant to treatment with
paclitaxel, while all were sensitive to treatment with vinblastine.
Table 2:
Sensitive (S) / Resistant (R)
Tumour type
BAL27862 Paclitaxel Vinblastine
GXF251 S R S
Gastric
GXF97 R R S
LXFL529 S R S
Lung
LXFA629 R R S
Immunohistochemistry analysis was performed in order to measure tumour
cell BUBR1 protein expression in the same tumours maintained as xenografts.
Analysis of whole-tumour BUBR1 levels indicated that BUBR1 levels varied between
the different tumours (Figure 16).
Based on the colony outgrowth assay and the same IC criteria, there was
no association between paclitaxel or vinblastine resistance and low BUBR1
expression levels. This is evident since for the gastric tumour type, both models were
resistant to paclitaxel and yet for GXF 97 the BUBR1 levels were much lower than in
GXF 251. The same lack of association was true for the vinca alkaloid, vinblastine in
the gastric model, since both these tumours were sensitive to vinblastine. This lack of
association was repeated in the lung tumour models. Thus BUBR1 levels were
shown to be unsuitable as a reliable biomarker of resistance to the conventional
microtubule agents paclitaxel and vinblastine in patient-derived tumour models.
Surprisingly, in contrast, when the BAL27862 resistance data, as defined by
the colony outgrowth assay, was compared with the BUBR1 level, BUBR1
expression was shown to be lower only in the resistant tumours and not in the
sensitive tumours derived from the same tumour histotype (compare Figure 16 with
Table 2). Low BUBR1 levels were therefore consistently indicative of resistance to
BAL2786. Thus BUBR1 levels were shown to be a biomarker of resistance for the
compound according to the invention, BAL27862.
Example 6: BUBR1 RNA versus protein expression levels.
In order to show that BUBR1 RNA expression levels reflect protein
expression levels, and hence that RNA expression levels can be used in the
prediction of resistance to BAL27862, expression levels were measured on both the
RNA and protein levels as follows. Whole cell protein extracts were prepared from
HeLa and H460 cell lines and analysed by immunoblot for BUBR1 protein expression
(Figure 17B). RNA samples were prepared from the same cell passage, and
quantitative RT-PCR was performed (Figure 17A). Comparison of the immunoblot
data (Figure 17B) and the RT-PCR data (Figure 17A), indicated that there was a
good correlation between protein and RNA expression levels for BUBR1 in these
lines.
List of abbreviations
A549 human non-small cell lung cancer cell line
BCA bicinchoninic acid
Bcl-2 B-cell lymphoma 2 protein
BRCA1 breast cancer type 1 susceptibility protein
BrdU bromodeoxyuridine
BSA bovine serum albumin
CCD charged-coupled device
cDNA complementary deoxyribonucleic acid
CA-125 cancer antigen 125
CREST limited scleroderma syndrome
DAB 3,3-diaminobenzidine
DMSO Dimethylsulphoxide
DMEM Dulbecos modified essential medium
DNA Deoxyribonucleic acid
dUTP 2´-Deoxyuridine 5´-Triphosphate
EDTA/EGTA Ethylendiamintetraacetate/ Ethyleneglycol-bis(β-aminoethyl)-
N,N,N′,N′-tetraacetate
ELISA enzyme-linked immunosorbent assay
ErbB-2 human epidermal growth factor receptor 2
EtOH Ethanol
FACS fluorescence activated cell scan/sorting
FCS/FBS foetal calf / foetal bovine serum
G2/M transition from G2 to the mitotic phase in the cell cycle
GXF 251 patient-derived gastric cancer
GXF 97 patient-derived gastric cancer
HCT116 human colorectal carcinoma cell line
HeLa human squamous cell cancer cell line
HEPES 4-(2-Hydroxyethyl)piperazineethanesulphonic acid
Hoe33342 2'-(4'-Ethoxyphenyl)(4-methylpiperazinyl)-2,5'-bis-1H-
benzimidazole trihydrochloride trihydrate
H460 human non-small-cell lung cancer cell line
IgA immunoglobulin A
IgG immunoglobulin G
IHC immunohistochemistry
ISET Isolation by size of epithelial tumor cells
LXFA 629 patient-derived lung carcinoma cells
LXFL 529 patient-derived lung carcinoma cells
MALDI matrix-assisted-laser-desorption/ionisation mass-
spectrometry
MALDI-TOF matrix-assisted-laser-desorption/ionisation–time-of-flight-
mass-spectrometry
MCF-7 human mammary carcinoma cell line
mRNA messenger ribonucleic acid
MTS 3-(4,5-dimethylthiazolyl)(3-carboxymethoxyphenyl)(4-
sulphophenyl)-2H-tetrazolium
NaCl Sodium chloride
NaF Sodium fluoride
NCBI National center for Biotechnology Information
NSCLC non-small cell lung cancer
NP40 Nonidet P40
NTC non-template control
PBS phosphate buffered saline
PCR polymerase chain reaction
P-gp P-glycoprotein
PMSF phenylmethylsulphonyl fluoride
PSA prostate-specific antigen
PVDF Polyvinylidene fluoride
RANO response assessment for high-grade gliomas
RECIST response evaluation criteria in solid tumours
READS restriction enzyme amplification of digested cDNAs
RPMI-1640 cell culture medium used for culturing transformed and non-
transformed eukaryotic cells and cell lines
RT-PCR real-time polymerase chain reaction
SAGE serial analysis of gene expression
SDS sodium dodecyl sulphate
SELDI surface enhanced laser desorption/Ionization mass-
spectrometry
SELDI-TOF surface enhanced laser desorption/Ionisation–
time-of-flight-mass-spectrometry
SEQ. ID No. sequence identification number
siRNA small inhibitory ribonucleic acid
SKBR3 human mammary carcinoma cell line
SKOV3 human ovarian carcinoma cell line
TUNEL terminal deoxynucleotidyl transferase dUTP nick end labeling
TX-100 Triton-X100
YO-PRO fluorescent, monomeric cyanine, nucleic acid stain
In this specification where reference has been made to patent specifications,
other external documents, or other sources of information, this is generally for the
purpose of providing a context for discussing the features of the invention. Unless
specifically stated otherwise, reference to such external documents is not to be
construed as an admission that such documents, or such sources of information, in any
jurisdiction, are prior art, or form part of the common general knowledge in the art.
In the description in this specification reference may be made to subject matter
that is not within the scope of the claims of the current application. That subject matter
should be readily identifiable by a person skilled in the art and may assist in putting into
practice the invention as defined in the claims of this application.
Claims (28)
1. Use of BUBR1 as a biomarker for predicting the response to a compound, wherein the compound is a compound of general formula I 5 wherein R represents phenyl, thienyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower 10 alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are 15 methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by hydroxy or lower alkoxy; R represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; 2 3 6 R , R and R represent hydrogen; R and R , independently of each other, represent hydrogen, lower alkyl or lower 25 alkoxy; or R and R together represent methylenedioxy; and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of prodrugs thereof; or wherein R represents phenyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, 10 acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower 15 alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; X represents oxygen; R represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; 2 3 6 R , R and R represent hydrogen; R and R , independently of each other, represent hydrogen, lower alkyl or lower 25 alkoxy; or R and R together represent methylenedioxy; and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of prodrugs thereof, and wherein the prefix lower denotes a radical having up to and including a 30 maximum of 7 carbon atoms, and wherein the response is of a disease in a subject and the biomarker BUBR1 is measured ex vivo in a sample or samples taken from the human or animal body.
2. Use according to claim 1, wherein the sample or samples are taken from the human body
3. Use according to claim 1 or 2, wherein in the compound of general formula I 5 R represents phenyl or pyridinyl; wherein phenyl is optionally substituted by one or two substituents independently selected from lower alkyl, lower alkoxy, amino, acetylamino, halogen and nitro; and wherein pyridinyl is optionally substituted by amino or halogen; 10 X represents a group C=O; R represents hydrogen or cyano-lower alkyl; 2 3 4 5 6 R , R , R , R and R represent hydrogen; 15 and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of prodrugs thereof, and wherein the prefix lower denotes a radical having up to and including a maximum of 7 carbon atoms.
4. Use according to any one of claims 1 to 3, wherein the compound is represented by the following formula 25 wherein R, Y and R are defined as follows: R Y R O CH CH CN O CH CH CN HN N or pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of prodrugs thereof.
5. Use according to any one of claims 1 to 4 wherein the compound is or pharmaceutically acceptable salts, solvates, polymorphs, prodrugs and salts of prodrugs thereof.
6. Use according to any one of claims 1 to 5, wherein the prefix lower denotes a radical having up to and including a maximum of 4 carbon atoms. 10
7. Use according to any one of claims 1 to 6, wherein an amide of the compound of formula I with glycine, alanine or lysine is used, the amide being formed from an amino group present within the R group of the compound of general formula I as defined in any one of claims 1 to 6 and the carboxy group of glycine, alanine or lysine.
8. Use according to claim 7, wherein the compound is or a pharmaceutically acceptable salt thereof.
9. Use according to claim 8, wherein the pharmaceutically acceptable salt is a hydrochloride salt or dihydrochloride salt.
10. Use according to any one of claims 1 to 9, for predicting the resistance 10 of a disease in a subject to said compound.
11. Use according to any one of claims 1 to 10, wherein the disease is a neoplastic disease or autoimmune disease.
12. Use according to claim 11, wherein the disease is cancer.
13. Use according to any one of claims 1 or 12, wherein the disease is 15 selected from the group consisting of breast cancer, prostate cancer, cervical cancer, ovarian cancer, gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, brain cancer, neuroendocrine cancer, lung cancer, kidney cancer, hematological malignancies, melanoma and sarcomas.
14. Use according to claim 13, wherein the cancer is selected from the group consisting of ovarian cancer, breast cancer, gastric cancer, pancreatic cancer, 5 colon cancer, lung cancer and cervical cancer.
15. Use according to claim 14, wherein the cancer is selected from the group consisting of lung cancer and gastric cancer.
16. Use according to any one of claims 1 to 15, wherein a lower level of BUBR1 in the sample from the subject relative to a standard value or set of standard 10 values predicts resistance.
17. Use according to claim 16, wherein lower BUBR1 levels in a sample or samples i) relative to a standard value or set of standard values from subjects with the same tumour histotype; or 15 ii) taken after treatment initiation and compared to a sample or samples taken from the same subject before treatment initiation; or iii) relative to a standard value or set of standard values from normal cells, tissue or body fluid; are predictive of resistance. 20
18. Use according to any one of claims 1 to 17, wherein the biomarker is used to select subjects suffering or predisposed to suffering from a disease, for treatment with a compound of general formula I or pharmaceutically acceptable salt, solvate, polymorph, prodrug or salt of prodrug thereof as defined in any one of claims 1 to 9.
19. Use according to claim 19, wherein the disease is cancer.
20. Use according to any one of claims 1 to 18, wherein the sample is derived from tumour tissue, normal tissue, cell lines or circulating tumour cells.
21. Use according to claim 19, wherein the sample is derived from tumour 5 tissue.
22. A method for predicting in a subject suffering of a cancer the response of that cancer to a compound of general formula I or to a pharmaceutically acceptable salt, solvate, polymorph, prodrug or salt of prodrug thereof as defined in any one of claims 1 to 9, comprising the steps of: 10 a) measuring ex vivo a level of BUBR1 in a sample pre-obtained from tumour tissue or circulating tumour cells of the subject to obtain a value or values representing this level; and b) comparing the value or values from step a) to a standard value or set of standard values from subjects with the same cancer type, 15 wherein a lower BUBR1 level in the sample relative to the standard value or set of standard values is predictive of resistance of the subject's cancer to the compound of formula (I) or to the pharmaceutically acceptable salt, solvate, polymorph, prodrug or salt of prodrug thereof.
23. Use of a compound of general formula I or of a pharmaceutically 20 acceptable salt, solvate, polymorph, prodrug or salt of prodrug thereof, as defined in any one of claims 1 to 9, for the preparation of a pharmaceutical composition for treating a cancer in a subject in need thereof, wherein the subject is selected for treatment with the compound of general formula I or with the salt, solvate, polymorph, prodrug or salt of prodrug thereof, as defined in any one of claims 1 to 9, if the level 25 of BUBR1, measured ex vivo in a sample taken from the subject, is not lower than a standard value or set of standard values from subjects with the same tumour histotype or from normal cells, tissue or body fluid.
24. A kit when used for predicting the response to a compound of general formula I or a pharmaceutically acceptable salt, solvate, polymorph, prodrug or salt of prodrug thereof, as defined in any one of claims 1 to 9, comprising reagents necessary for measuring a level of BUBR1 in a sample taken from a subject with a 5 cancer, and further comprising a comparator module which comprises a standard value or set of standard values of a level of BUBR1 taken from samples of tumour tissue or circulating tumour cells of subjects with a cancer of the same histotype to which the level of BUBR1 in the sample is compared.
25. The kit according to claim 24, wherein the reagents comprise a capture 10 reagent comprising a detector for BUBR1 and a detector reagent.
26. The kit according to claim 24 or claim 25, wherein the capture reagent is an antibody.
27. The kit according to any one of claims 24 to 26, wherein the kit comprises a compound of the following formula or a pharmaceutically acceptable salt 15 thereof,
28. The kit according to claim 27, wherein the pharmaceutically acceptable salt is the dihydrochloride salt.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11151677 | 2011-01-21 | ||
EP11151677.9 | 2011-01-21 | ||
PCT/EP2012/050818 WO2012098207A1 (en) | 2011-01-21 | 2012-01-19 | Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ611805A NZ611805A (en) | 2015-05-29 |
NZ611805B2 true NZ611805B2 (en) | 2015-09-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10067120B2 (en) | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | |
US9970938B2 (en) | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | |
US10656162B2 (en) | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | |
EP2666015B1 (en) | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles | |
AU2012208521B9 (en) | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles | |
NZ611805B2 (en) | Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles | |
NZ611525B2 (en) | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles |